Publications
2024
Physiologically based pharmacokinetic modeling of drug–drug interactions between ritonavir‐boosted atazanavir and rifampicin in pregnancy
Atoyebi, S., Montanha, M. C., Nakijoba, R., Orrell, C., Mugerwa, H., Siccardi, M., . . . Waitt, C. (n.d.). Physiologically based pharmacokinetic modeling of drug–drug interactions between ritonavir‐boosted atazanavir and rifampicin in pregnancy. CPT: Pharmacometrics & Systems Pharmacology. doi:10.1002/psp4.13268
Pharmacokinetics and Safety of Twice-daily Ritonavir-boosted Atazanavir With Rifampicin.
Gausi, K., Mugerwa, H., Siccardi, M., Montanha, M. C., Lamorde, M., Wiesner, L., . . . Waitt, C. (2024). Pharmacokinetics and Safety of Twice-daily Ritonavir-boosted Atazanavir With Rifampicin.. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 78(5), 1246-1255. doi:10.1093/cid/ciad700
DeepARV: ensemble deep learning to predict drug-drug interaction of clinical relevance with antiretroviral therapy.
Pham, T., Ghafoor, M., Grañana-Castillo, S., Marzolini, C., Gibbons, S., Khoo, S., . . . Siccardi, M. (2024). DeepARV: ensemble deep learning to predict drug-drug interaction of clinical relevance with antiretroviral therapy.. NPJ systems biology and applications, 10(1), 48. doi:10.1038/s41540-024-00374-0
Physiologically-based pharmacokinetic modelling of long-acting injectable cabotegravir and rilpivirine in pregnancy
Atoyebi, S., Bunglawala, F., Cottura, N., Grañana-Castillo, S., Montanha, M., Olagunju, A., . . . Waitt, C. (2024). Physiologically-based pharmacokinetic modelling of long-acting injectable cabotegravir and rilpivirine in pregnancy. British Journal of Clinical Pharmacology. doi:10.1111/bcp.16006
2023
PA-727 Physiologically-based pharmacokinetic modelling of drug-drug interactions between ritonavir-boosted atazanavir and rifampicin in pregnancy
Atoyebi, S., Montanha, M. C., Najjemba, L., Orrell, C., Jennings, L., Mugerwa, H., . . . Waitt, C. (2023). PA-727 Physiologically-based pharmacokinetic modelling of drug-drug interactions between ritonavir-boosted atazanavir and rifampicin in pregnancy. In Abstracts of Poster and e-Poster Presentations (pp. A114.2-A114). BMJ Publishing Group Ltd. doi:10.1136/bmjgh-2023-edc.279
Physiologically Based Pharmacokinetic Modelling of Cabotegravir Microarray Patches in Rats and Humans.
Kinvig, H., Rajoli, R. K. R., Pertinez, H., Vora, L. K., Volpe-Zanutto, F., Donnelly, R. F., . . . Owen, A. (2023). Physiologically Based Pharmacokinetic Modelling of Cabotegravir Microarray Patches in Rats and Humans.. Pharmaceutics, 15(12), 2709. doi:10.3390/pharmaceutics15122709
Dose Optimization of the Quinine-phenobarbital Co-administration in Cerebral Malaria Patients: A Physiologically-based Pharmacokinetic Modeling Approach
Sae-Heng, T., Rajoli, R. K. R., Siccardi, M., & Na-Bangchang, K. (2023). Dose Optimization of the Quinine-phenobarbital Co-administration in Cerebral Malaria Patients: A Physiologically-based Pharmacokinetic Modeling Approach. In Novel Aspects on Pharmaceutical Research Vol. 5 (pp. 117-138). B P International (a part of SCIENCEDOMAIN International). doi:10.9734/bpi/napr/v5/19726d
Physiologically-based pharmacokinetic modelling of long-acting injectable cabotegravir and rilpivirine in pregnancy
General Framework to Quantitatively Predict Pharmacokinetic Induction Drug-Drug Interactions Using In Vitro Data
Granana-Castillo, S., Williams, A., Pham, T., Khoo, S., Hodge, D., Akpan, A., . . . Siccardi, M. (2023). General Framework to Quantitatively Predict Pharmacokinetic Induction Drug-Drug Interactions Using In Vitro Data. CLINICAL PHARMACOKINETICS, 62(5), 737-748. doi:10.1007/s40262-023-01229-3
Effect of double-dose levonorgestrel subdermal implant in women taking efavirenz-based antiretroviral therapy: The DoubLNG pharmacokinetic study.
Cirrincione, L. R., Nakalema, S., Chappell, C. A., Byakika-Kibwika, P., Kyohairwe, I., Winchester, L., . . . Scarsi, K. K. (2023). Effect of double-dose levonorgestrel subdermal implant in women taking efavirenz-based antiretroviral therapy: The DoubLNG pharmacokinetic study.. Contraception, 109975. doi:10.1016/j.contraception.2023.109975
Evaluating Islatravir Administered Via Microneedle Array Patch for Long-Acting HIV Pre-exposure Prophylaxis Using Physiologically Based Pharmacokinetic Modelling (vol 47, pg 855, 2022)
Kinvig, H., Cottura, N., Lloyd, A., Frivold, C., Mistilis, J., Jarrahian, C., & Siccardi, M. (2023). Evaluating Islatravir Administered Via Microneedle Array Patch for Long-Acting HIV Pre-exposure Prophylaxis Using Physiologically Based Pharmacokinetic Modelling (vol 47, pg 855, 2022). EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 48(1), 119. doi:10.1007/s13318-022-00811-7
Physiologically-based pharmacokinetic modelling of the 2-monthly regimen of long-acting injectable rilpivirine administered in pregnancy
Atoyebi, S., Siccardi, M., & Waitt, C. (2023). Physiologically-based pharmacokinetic modelling of the 2-monthly regimen of long-acting injectable rilpivirine administered in pregnancy. In BRITISH JOURNAL OF PHARMACOLOGY Vol. 180 (pp. 338-340). Retrieved from https://www.webofscience.com/
Plasma and intracellular concentrations ritonavir, atazanavir and dolutegravir in the presence of rifampicin in the context of a dose escalation study
De Nicolo, A., De Vivo, E. D., Mugerwa, H., Nakabuye, S., Namusanje, J., Kobusingye, J., . . . D'Avolio, A. (2023). Plasma and intracellular concentrations ritonavir, atazanavir and dolutegravir in the presence of rifampicin in the context of a dose escalation study. In BRITISH JOURNAL OF PHARMACOLOGY Vol. 180 (pp. 215-216). Retrieved from https://www.webofscience.com/
2022
Evaluation of drug-drug interaction between rilpivirine and rifapentine using PBPK modelling
Granana-Castillo, S., Montanha, M. C., Bearon, R., Khoo, S., & Siccardi, M. (2022). Evaluation of drug-drug interaction between rilpivirine and rifapentine using PBPK modelling. FRONTIERS IN PHARMACOLOGY, 13. doi:10.3389/fphar.2022.1076266
The LEAP Process: Streamlining the Development of Long-Acting Products and Formulations for Infectious Diseases
Flexner, C., Siccardi, M., Bunglawala, F., & Owen, A. (2022). The LEAP Process: Streamlining the Development of Long-Acting Products and Formulations for Infectious Diseases. CLINICAL INFECTIOUS DISEASES, 75, S502-S509. doi:10.1093/cid/ciac750
Evaluating Islatravir Administered Via Microneedle Array Patch for Long-Acting HIV Pre-exposure Prophylaxis Using Physiologically Based Pharmacokinetic Modelling
Kinvig, H., Cottura, N., Lloyd, A., Frivold, C., Mistilis, J., Jarrahian, C., & Siccardi, M. (2022). Evaluating Islatravir Administered Via Microneedle Array Patch for Long-Acting HIV Pre-exposure Prophylaxis Using Physiologically Based Pharmacokinetic Modelling. EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 47(6), 855-868. doi:10.1007/s13318-022-00793-6
Predicting Drug-Drug Interactions between Rifampicin and Ritonavir-Boosted Atazanavir Using PBPK Modelling (vol 61, pg 375, 2022)
Montanha, M. C., Fabrega, F., Howarth, A., Cottura, N., Kinvig, H., Bunglawala, F., . . . Siccardi, M. (2022). Predicting Drug-Drug Interactions between Rifampicin and Ritonavir-Boosted Atazanavir Using PBPK Modelling (vol 61, pg 375, 2022). CLINICAL PHARMACOKINETICS, 61(11), 1641. doi:10.1007/s40262-022-01178-3
Pharmacokinetics of levonorgestrel and etonogestrel contraceptive implants over 48 weeks with rilpivirine- or darunavir-based antiretroviral therapy
Nakalema, S., Chappell, C. A., Pham, M., Byakika-Kibwika, P., Kaboggoza, J., Walimbwa, S. I., . . . Lamorde, M. (2022). Pharmacokinetics of levonorgestrel and etonogestrel contraceptive implants over 48 weeks with rilpivirine- or darunavir-based antiretroviral therapy. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 77(11), 3144-3152. doi:10.1093/jac/dkac296
A physiologically based pharmacokinetic model to predict pegylated liposomal doxorubicin disposition in rats and human
Montanha, M. C., Howarth, A., Mohamed, D. A., Loier, E., Main, L., Rosslein, M., . . . Siccardi, M. (2022). A physiologically based pharmacokinetic model to predict pegylated liposomal doxorubicin disposition in rats and human. DRUG DELIVERY AND TRANSLATIONAL RESEARCH, 12(9), 2178-2186. doi:10.1007/s13346-022-01175-w
Drug-Drug Interactions in People Living With HIV at Risk of Hepatic and Renal Impairment: Current Status and Future Perspectives
Cottura, N., Kinvig, H., Granana-Castillo, S., Wood, A., & Siccardi, M. (2022). Drug-Drug Interactions in People Living With HIV at Risk of Hepatic and Renal Impairment: Current Status and Future Perspectives. JOURNAL OF CLINICAL PHARMACOLOGY, 62(7), 835-846. doi:10.1002/jcph.2025
Drug interactions: a review of the unseen danger of experimental COVID-19 therapies (vol 75, pg 3417, 2020)
Hodge, D., Marra, F., Marzolini, C., Boyle, A., Gibbons, S., Siccardi, M., . . . Khoo, S. (2022). Drug interactions: a review of the unseen danger of experimental COVID-19 therapies (vol 75, pg 3417, 2020). JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 77(7), 2050. doi:10.1093/jac/dkac111
A Physiologically Based Pharmacokinetic Model to Predict Pegylated Liposomal Doxorubicin Disposition in Rats and Human
PBPK MODELING OF LONG-ACTING INJECTABLE CABOTEGRAVIR IN PREGNANCY
Atoyebi, S., Bunglawala, F., Cottura, N., Camotti-Montanha, M., Siccardi, M., & Waitt, C. (2022). PBPK MODELING OF LONG-ACTING INJECTABLE CABOTEGRAVIR IN PREGNANCY. In Fazila Bunglawala. Conference on Retroviruses and Opportunistic Infections.
PBPK Modelling of Dexamethasone in Patients With COVID-19 and Liver Disease
Montanha, M. C., Cottura, N., Booth, M., Hodge, D., Bunglawala, F., Kinvig, H., . . . Siccardi, M. (2022). PBPK Modelling of Dexamethasone in Patients With COVID-19 and Liver Disease. FRONTIERS IN PHARMACOLOGY, 13. doi:10.3389/fphar.2022.814134
Physiologically based pharmacokinetic modelling of long-acting rilpivirine in pregnancy
Atoyebi, S., Granana-Castillo, S., Siccardi, M., & Waitt, C. (2022). Physiologically based pharmacokinetic modelling of long-acting rilpivirine in pregnancy. In JOURNAL OF THE INTERNATIONAL AIDS SOCIETY Vol. 25 (pp. 186-187). Retrieved from https://www.webofscience.com/
2021
Evaluating the impact of systematic hydrophobic modification of model drugs on the control, stability and loading of lipid-based nanoparticles
Hogarth, C., Arnold, K., McLauchlin, A., Rannard, S. P., Siccardi, M., & McDonald, T. O. (2021). Evaluating the impact of systematic hydrophobic modification of model drugs on the control, stability and loading of lipid-based nanoparticles. JOURNAL OF MATERIALS CHEMISTRY B, 9(48), 9874-9884. doi:10.1039/d1tb02297k
Physiologically based pharmacokinetic modeling for dose optimization of quinine-phenobarbital coadministration in patients with cerebral malaria
Sae-Heng, T., Rajoli, R. K. R., Siccardi, M., Karbwang, J., & Na-Bangchang, K. (2021). Physiologically based pharmacokinetic modeling for dose optimization of quinine-phenobarbital coadministration in patients with cerebral malaria. CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 11(1), 104-115. doi:10.1002/psp4.12737
In vitro assessment of the potential for dolutegravir to affect hepatic clearance of levonorgestrel
Roberts, O., Kinvig, H., Owen, A., Lamorde, M., Siccardi, M., & Scarsi, K. K. (2021). In vitro assessment of the potential for dolutegravir to affect hepatic clearance of levonorgestrel. HIV MEDICINE, 22(10), 898-906. doi:10.1111/hiv.13136
Predicting Drug-Drug Interactions between Rifampicin and Ritonavir-Boosted Atazanavir Using PBPK Modelling
Montanha, M. C., Fabrega, F., Howarth, A., Cottura, N., Kinvig, H., Bunglawala, F., . . . Siccardi, M. (2021). Predicting Drug-Drug Interactions between Rifampicin and Ritonavir-Boosted Atazanavir Using PBPK Modelling. CLINICAL PHARMACOKINETICS. doi:10.1007/s40262-021-01067-1
Methodological needs in the quality and safety characterisation of nanotechnology-based health products: Priorities for method development and standardisation
Halamoda-Kenzaoui, B., Vandebriel, R. J., Howarth, A., Siccardi, M., David, C. A. W., Liptrott, N. J., . . . Caputo, F. (2021). Methodological needs in the quality and safety characterisation of nanotechnology-based health products: Priorities for method development and standardisation. JOURNAL OF CONTROLLED RELEASE, 336, 192-206. doi:10.1016/j.jconrel.2021.06.016
Recommendations for Dosing of Repurposed COVID-19 Medications in Patients with Renal and Hepatic Impairment
Marra, F., Smolders, E. J., El-Sherif, O., Boyle, A., Davidson, K., Sommerville, A. J., . . . Back, D. (2021). Recommendations for Dosing of Repurposed COVID-19 Medications in Patients with Renal and Hepatic Impairment. DRUGS IN R&D, 21(1), 9-27. doi:10.1007/s40268-020-00333-0
Clinical Data Combined With Modeling and Simulation Indicate Unchanged Drug-Drug Interaction Magnitudes in the Elderly
Stader, F., Courlet, P., Kinvig, H., Penny, M. A., Decosterd, L. A., Battegay, M., . . . Marzolini, C. (2021). Clinical Data Combined With Modeling and Simulation Indicate Unchanged Drug-Drug Interaction Magnitudes in the Elderly. CLINICAL PHARMACOLOGY & THERAPEUTICS, 109(2), 471-484. doi:10.1002/cpt.2017
Effect of ageing on antiretroviral drug pharmacokinetics using clinical data combined with modelling and simulation
Stader, F., Courlet, P., Kinvig, H., Battegay, M., Decosterd, L. A., Penny, M. A., . . . Marzolini, C. (2021). Effect of ageing on antiretroviral drug pharmacokinetics using clinical data combined with modelling and simulation. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 87(2), 458-470. doi:10.1111/bcp.14402
Long-acting drugs and formulations for the treatment and prevention of HIV infection
Flexner, C., Owen, A., Siccardi, M., & Swindells, S. (2021). Long-acting drugs and formulations for the treatment and prevention of HIV infection. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 57(1). doi:10.1016/j.ijantimicag.2020.106220
2020
Drug interactions: a review of the unseen danger of experimental COVID-19 therapies
Hodge, D., Marra, F., Marzolini, C., Boyle, A., Gibbons, S., Siccardi, M., . . . Khoo, S. (2020). Drug interactions: a review of the unseen danger of experimental COVID-19 therapies. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 75(12), 3417-3424. doi:10.1093/jac/dkaa340
The Current Landscape of Novel Formulations and the Role of Mathematical Modeling in Their Development
Cottura, N., Howarth, A., Rajoli, R. K. R., & Siccardi, M. (2020). The Current Landscape of Novel Formulations and the Role of Mathematical Modeling in Their Development. JOURNAL OF CLINICAL PHARMACOLOGY, 60, S77-S97. doi:10.1002/jcph.1715
The challenging pathway towards the identification of SARS-CoV-2/COVID-19 therapeutics
Siccardi, M., Schapiro, J., Di Perri, G., & Back, D. J. (2020). The challenging pathway towards the identification of SARS-CoV-2/COVID-19 therapeutics. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 75(9), 2381-2383. doi:10.1093/jac/dkaa272
Physiologically-based Pharmacokinetic (PBPK) Modeling for Prediction of the Optimal Dose Regimens of Quinine and Phenobarbital Co-administration in Adult Patients with Cerebral Malaria and Seizures
Saeheng, T., Karbwang, J., Rajoli, R. K. R., Siccardi, M., & Na-Bangchang, K. (2020). Physiologically-based Pharmacokinetic (PBPK) Modeling for Prediction of the Optimal Dose Regimens of Quinine and Phenobarbital Co-administration in Adult Patients with Cerebral Malaria and Seizures. doi:10.21203/rs.3.rs-53474/v1
Influence of selected polymorphisms in disposition genes on lumefantrine pharmacokinetics when coadministered with efavirenz
Adegbola, A. J., Rana, A., Adeagbo, B. A., Bolarinwa, R. A., Olagunju, A. E., Siccardi, M., . . . Bolaji, O. O. (2020). Influence of selected polymorphisms in disposition genes on lumefantrine pharmacokinetics when coadministered with efavirenz. PHARMACOGENETICS AND GENOMICS, 30(5), 96-106. doi:10.1097/FPC.0000000000000401
Predicting pharmacokinetics of a tenofovir alafenamide subcutaneous implant using PBPK modelling.
Rajoli, R. K. R., Demkovich, Z. R., Flexner, C., Owen, A., & Siccardi, M. (2020). Predicting pharmacokinetics of a tenofovir alafenamide subcutaneous implant using PBPK modelling.. Antimicrobial Agents and Chemotherapy. doi:10.1128/aac.00155-20
Physiologically-Based Pharmacokinetic Modeling for Optimal Dosage Prediction of Quinine Coadministered With Ritonavir-Boosted Lopinavir
Saeheng, T., Na-Bangchang, K., Siccardi, M., Rajoli, R. K. R., & Karbwang, J. (2020). Physiologically-Based Pharmacokinetic Modeling for Optimal Dosage Prediction of Quinine Coadministered With Ritonavir-Boosted Lopinavir. CLINICAL PHARMACOLOGY & THERAPEUTICS, 107(5), 1209-1220. doi:10.1002/cpt.1721
Physiologically Based Pharmacokinetic Modelling to Identify Pharmacokinetic Parameters Driving Drug Exposure Changes in the Elderly
Stader, F., Kinvig, H., Penny, M. A., Battegay, M., Siccardi, M., & Marzolini, C. (2020). Physiologically Based Pharmacokinetic Modelling to Identify Pharmacokinetic Parameters Driving Drug Exposure Changes in the Elderly. CLINICAL PHARMACOKINETICS, 59(3), 383-401. doi:10.1007/s40262-019-00822-9
Prediction of dolutegravir pharmacokinetics and dose optimization in neonates via physiologically based pharmacokinetic (PBPK) modelling
Bunglawala, F., Rajoli, R. K. R., Mirochnick, M., Owen, A., & Siccardi, M. (2020). Prediction of dolutegravir pharmacokinetics and dose optimization in neonates via physiologically based pharmacokinetic (PBPK) modelling. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 75(3), 640-647. doi:10.1093/jac/dkz506
2019
Using mechanistic physiologically-based pharmacokinetic models to assess prenatal drug exposure: Thalidomide <i>versus</i> efavirenz as case studies
Atoyebi, S. A., Rajoli, R. K. R., Adejuyigbe, E., Owen, A., Bolaji, O., Siccardi, M., & Olagunju, A. (2019). Using mechanistic physiologically-based pharmacokinetic models to assess prenatal drug exposure: Thalidomide <i>versus</i> efavirenz as case studies. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 140. doi:10.1016/j.ejps.2019.105068
Anhydrous nanoprecipitation for the preparation of nanodispersions of tenofovir disoproxil fumarate in oils as candidate long-acting injectable depot formulations
Hobson, J. J., Curley, P., Savage, A. C., Al-khouja, A., Siccardi, M., Flexner, C., . . . Rannard, S. P. (2019). Anhydrous nanoprecipitation for the preparation of nanodispersions of tenofovir disoproxil fumarate in oils as candidate long-acting injectable depot formulations. NANOSCALE ADVANCES, 1(11), 4301-4307. doi:10.1039/c9na00529c
Modelling the intradermal delivery of microneedle array patches for long-acting antiretrovirals using PBPK
Rajoli, R. K. R., Flexner, C., Chiong, J., Owen, A., Donnelly, R. F., Larraneta, E., & Siccardi, M. (2019). Modelling the intradermal delivery of microneedle array patches for long-acting antiretrovirals using PBPK. EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 144, 101-109. doi:10.1016/j.ejpb.2019.09.011
Effect of patient genetics on etonogestrel pharmacokinetics when combined with efavirenz or nevirapine ART
Neary, M., Chappell, C. A., Scarsi, K. K., Nakalema, S., Matovu, J., Achilles, S. L., . . . Lamorde, M. (2019). Effect of patient genetics on etonogestrel pharmacokinetics when combined with efavirenz or nevirapine ART. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 74(10), 3003-3010. doi:10.1093/jac/dkz298
Effect of CYP2B6 Metabolizer Status on Levonorgestrel Pharmacokinetics When Combined with Efavirenz-based Antiretroviral Therapy
Pham, M., Mbabzi, O., Neary, M. G., Nakalema, S., Campbell, K., Cirrincione, L., . . . Kimberly, S. (2019). Effect of CYP2B6 Metabolizer Status on Levonorgestrel Pharmacokinetics When Combined with Efavirenz-based Antiretroviral Therapy. In PK workshop. Amsterdam, Netherlands.
Predicting Drug-Drug Interactions Between Rifampicin and Long-Acting Cabotegravir and Rilpivirine Using Physiologically Based Pharmacokinetic Modeling
Rajoli, R. K. R., Curley, P., Chiong, J., Back, D., Flexner, C., Owen, A., & Siccardi, M. (2019). Predicting Drug-Drug Interactions Between Rifampicin and Long-Acting Cabotegravir and Rilpivirine Using Physiologically Based Pharmacokinetic Modeling. JOURNAL OF INFECTIOUS DISEASES, 219(11), 1735-1742. doi:10.1093/infdis/jiy726
Improving maraviroc oral bioavailability by formation of solid drug nanoparticles
Savage, A. C., Tatham, L. M., Siccardi, M., Scott, T., Vourvahis, M., Clark, A., . . . Owen, A. (2019). Improving maraviroc oral bioavailability by formation of solid drug nanoparticles. EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 138, 30-36. doi:10.1016/j.ejpb.2018.05.015
Towards a Maraviroc long-acting injectable nanoformulation
Tatham, L. M., Savage, A. C., Dwyer, A., Siccardi, M., Scott, T., Vourvahis, M., . . . Owen, A. (2019). Towards a Maraviroc long-acting injectable nanoformulation. EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 138, 92-98. doi:10.1016/j.ejpb.2018.04.009
Effect of tenofovir and abacavir on dolutegravir transport in vitro and in vivo
Neary, M. G., Tatham, L., Sharp, J., Ayuso, P., Abutaima, R., Box, H., . . . Owen, A. (2019, May 14). Effect of tenofovir and abacavir on dolutegravir transport in vitro and in vivo. In 20th International Workshop on Clinical Pharmacology of HIV, Hepatitis and Other Antiviral Drugs.. Hotel Oranje, Noordwijk, NL.
Repository Describing an Aging Population to Inform Physiologically Based Pharmacokinetic Models Considering Anatomical, Physiological, and Biological Age-Dependent Changes
Stader, F., Siccardi, M., Battegay, M., Kinvig, H., Penny, M. A., & Marzolini, C. (2019). Repository Describing an Aging Population to Inform Physiologically Based Pharmacokinetic Models Considering Anatomical, Physiological, and Biological Age-Dependent Changes. CLINICAL PHARMACOKINETICS, 58(4), 483-501. doi:10.1007/s40262-018-0709-7
Semi-solid pro-drug nanoparticles for long-acting delivery of water-soluble antiretroviral drugs for combination HIV therapies
Hobson, J., Al-Khouja, A., Curley, P., Flexner, C., Meyers, C., Owen, A., & Rannard, S. (2017). Semi-solid pro-drug nanoparticles for long-acting delivery of water-soluble antiretroviral drugs for combination HIV therapies. In ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY Vol. 254. Retrieved from https://www.webofscience.com/
Semi-solid prodrug nanoparticles for long-acting delivery of water-soluble antiretroviral drugs within combination HIV therapies
Hobson, J., Al-Khouja, A., Curley, P., Meyers, D., Flexner, C., Siccardi, M., . . . Rannard, S. P. (2019). Semi-solid prodrug nanoparticles for long-acting delivery of water-soluble antiretroviral drugs within combination HIV therapies. Nature Communications, 10. doi:10.1038/s41467-019-09354-z
Impact of pharmacogenetics and pregnancy on tenofovir and emtricitabine pharmacokinetics
Gini, J., Olagunju, A., Dickinson, L., Waitt, C., Neary, M., Else, L. J., . . . Khoo, S. (2019). Impact of pharmacogenetics and pregnancy on tenofovir and emtricitabine pharmacokinetics. PHARMACOGENOMICS, 20(4), 217-224. doi:10.2217/pgs-2018-0111
A comprehensive framework for physiologically based pharmacokinetic modelling in Matlab®.
Stader, F., Penny, M. A., Siccardi, M., & Marzolini, C. (2019). A comprehensive framework for physiologically based pharmacokinetic modelling in Matlab®.. CPT: pharmacometrics & systems pharmacology. doi:10.1002/psp4.12399
2018
Inhibitory Effects of Commonly Used Excipients on P-Glycoprotein in Vitro
Gurjar, R., Chan, C. Y. S., Curley, P., Sharp, J., Chiong, J., Rannard, S., . . . Owen, A. (2018). Inhibitory Effects of Commonly Used Excipients on P-Glycoprotein in Vitro. MOLECULAR PHARMACEUTICS, 15(11), 4835-4842. doi:10.1021/acs.molpharmaceut.8b00482
Effect of Pregnancy on the Pharmacokinetic Interaction between Efavirenz and Lumefantrine in HIV-Malaria Coinfection
Adegbola, A., Abutaima, R., Olagunju, A., Ijarotimi, O., Siccardi, M., Owen, A., . . . Bolaji, O. (2018). Effect of Pregnancy on the Pharmacokinetic Interaction between Efavirenz and Lumefantrine in HIV-Malaria Coinfection. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 62(10). doi:10.1128/AAC.01252-18
Derivation of CYP3A4 and CYP2B6 degradation rate constants in primary human hepatocytes: A siRNA-silencing-based approach
Chan, C. Y. S., Roberts, O., Rajoli, R. K. R., Liptrott, N. J., Siccardi, M., Almond, L., & Owen, A. (2018). Derivation of CYP3A4 and CYP2B6 degradation rate constants in primary human hepatocytes: A siRNA-silencing-based approach. DRUG METABOLISM AND PHARMACOKINETICS, 33(4), 179-187. doi:10.1016/j.dmpk.2018.01.004
Modelling the long-acting administration of anti-tuberculosis agents using PBPK: a proof of concept study
Rajoli, R. K. R., Podany, A. T., Moss, D. M., Swindells, S., Flexner, C., Owen, A., & Siccardi, M. (2018). Modelling the long-acting administration of anti-tuberculosis agents using PBPK: a proof of concept study. INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 22(8), 937-944. doi:10.5588/ijtld.17.0515
Analysis of Clinical Drug-Drug Interaction Data To Predict Magnitudes of Uncharacterized Interactions between Antiretroviral Drugs and Comedications
Stader, F., Kinvig, H., Battegay, M., Khoo, S., Owen, A., Siccardi, M., & Marzolini, C. (2018). Analysis of Clinical Drug-Drug Interaction Data To Predict Magnitudes of Uncharacterized Interactions between Antiretroviral Drugs and Comedications. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 62(7). doi:10.1128/AAC.00717-18
The emerging role of physiologically based pharmacokinetic modelling in solid drug nanoparticle translation
Siccardi, M., Rannard, S., & Owen, A. (2018). The emerging role of physiologically based pharmacokinetic modelling in solid drug nanoparticle translation. Advanced Drug Delivery Reviews, 131, 116-121. doi:10.1016/j.addr.2018.06.016
Improved Oral In Vivo Pharmacokinetics of Novel Oil in Water Solid Drug Nanoparticle formulations of Tenofovir Disoproxil Fumarate for the treatment of HIV
Curley, P., Hobson, J., David, C., Box, H., Neary, M. G., Sharp, J., . . . Owen, A. (n.d.). Improved Oral In Vivo Pharmacokinetics of Novel Oil in Water Solid Drug Nanoparticle formulations of Tenofovir Disoproxil Fumarate for the treatment of HIV. In CLINAM European Foundation for Clinical Nanomedicine.
Physiologically-based pharmacokinetic modelling of infant exposure to efavirenz through breastfeeding
Olagunju, A., Rajoli, R. K. R., Atoyebi, S. A., Khoo, S., Owen, A., & Siccardi, M. (2018). Physiologically-based pharmacokinetic modelling of infant exposure to efavirenz through breastfeeding. AAS Open Research, 1(16). doi:10.12688/aasopenres.12860.1
Development, validation and utilization of a highly sensitive LC-MS/MS method for quantification of levonorgestrel released from a subdermal implant in human plasma
Cirrincione, L. R., Penchala, S. D., Scarsi, K. K., Podany, A. T., Winchester, L. C., Back, D. J., . . . Else, L. J. (2018). Development, validation and utilization of a highly sensitive LC-MS/MS method for quantification of levonorgestrel released from a subdermal implant in human plasma. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 1084, 106-112. doi:10.1016/j.jchromb.2018.03.023
Development of prodrug approaches for long-acting nanoformulations of emtricitabine-based regimens
Al-Khouja, A., Hobson, J., Meyers, D., Curley, P., Siliciano, J., Siliciano, R., . . . Meyers, C. (2017). Development of prodrug approaches for long-acting nanoformulations of emtricitabine-based regimens. In ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY Vol. 254. Retrieved from https://www.webofscience.com/
Physiologically based pharmacokinetic modelling prediction of the effects of dose adjustment in drug–drug interactions between levonorgestrel contraceptive implants and efavirenz-based ART
Roberts, O., Rajoli, R. K. R., Back, D. J., Owen, A., Darin, K. M., Fletcher, C. V., . . . Siccardi, M. (2018). Physiologically based pharmacokinetic modelling prediction of the effects of dose adjustment in drug–drug interactions between levonorgestrel contraceptive implants and efavirenz-based ART. Journal of Antimicrobial Chemotherapy, 73(4), 1004-1012. doi:10.1093/jac/dkx515
Maraviroc solid drug nanoparticles with improved oral pharmacokinetics
Tatham, L., Savage, A. C., Dwyer, A. B., Siccardi, M., Scott, T., Vourvahis, M., . . . Owen, A. (2018). Maraviroc solid drug nanoparticles with improved oral pharmacokinetics. In CROI. Boston MA.
Towards a Long-Acting Injectable (LAI) Formulation For Maraviroc
Tatham, L., Dwyer, A. B., Savage, A. C., Siccardi, M., Scott, T., Vourvahis, M., . . . Owen, A. (2018). Towards a Long-Acting Injectable (LAI) Formulation For Maraviroc. In CROI. Boston MA.
CYP2B6 variants alter etonogestrel pharmacokinetics when combined with efavirenz.
Neary, M. G., Chappell, C., Scarsi, K., Nakalema, S., Matovu, J., Achilles, S., . . . Lamorde, M. (2018, March 5). CYP2B6 variants alter etonogestrel pharmacokinetics when combined with efavirenz.. In CROI. Boston, MA, USA.
In Silico Dose Prediction for Long-Acting Rilpivirine and Cabotegravir Administration to Children and Adolescents.
Rajoli, R. K. R., Back, D. J., Rannard, S., Meyers, C. F., Flexner, C., Owen, A., & Siccardi, M. (2018). In Silico Dose Prediction for Long-Acting Rilpivirine and Cabotegravir Administration to Children and Adolescents.. Clinical pharmacokinetics, 57(02), 255-266. doi:10.1007/s40262-017-0557-x
Long-acting formulations for the treatment of latent tuberculous infection: opportunities and challenges
Swindells, S., Siccardi, M., Barrett, S. E., Olsen, D. B., Grobler, J. A., Podany, A. T., . . . Flexner, C. (2018). Long-acting formulations for the treatment of latent tuberculous infection: opportunities and challenges. INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 22(2), 125-132. doi:10.5588/ijtld.17.0486
Development of Prodrug Approaches for Long-Acting Nanoformulations of Emtricitabine-Based Regimens
Al-Khouja, A., Hobson, J. J., Henriquez, S., Meyers, D., Curley, P., Siccardi, M., . . . Meyers, C. L. F. (2018). Development of Prodrug Approaches for Long-Acting Nanoformulations of Emtricitabine-Based Regimens. In FASEB JOURNAL Vol. 32. Retrieved from https://www.webofscience.com/
Mechanisms of Drug Interactions II: Transport Proteins
Moss, D. M., Siccardi, M., & Marzolini, C. (2018). Mechanisms of Drug Interactions II: Transport Proteins. In Drug Interactions in Infectious Diseases: Mechanisms and Models of Drug Interactions (pp. 49-85). Springer International Publishing. doi:10.1007/978-3-319-72422-5_3
Prediction and optimization of photo-activated curcumin dosage schedule in human, a promising antimicrobial candidate: A physiologically-based pharmacokinetic (PBPK) modeling
Saeheng, T., Na-Bangchang, K., Rajoli, R. K. R., Siccardi, M., Owen, A., & Laothavorn, J. (2018). Prediction and optimization of photo-activated curcumin dosage schedule in human, a promising antimicrobial candidate: A physiologically-based pharmacokinetic (PBPK) modeling. Proceedings for Annual Meeting of The Japanese Pharmacological Society, WCP2018(0). doi:10.1254/jpssuppl.wcp2018.0_po1-11-30
Solid drug nanoparticles synthesised using spontaneous nanoprecipitation of tenofovir disoproxil fumerate: From proof of concept to in vivo pharmacokinetics of improved oral dosage
Hobson, J., Curley, P., Al-khouja, A., Siccardi, M., Flexner, C., Meyers, C., . . . Rannard, S. (2018). Solid drug nanoparticles synthesised using spontaneous nanoprecipitation of tenofovir disoproxil fumerate: From proof of concept to in vivo pharmacokinetics of improved oral dosage. In ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY Vol. 256. Retrieved from https://www.webofscience.com/
2017
Incompatibility of chemical protein synthesis inhibitors with accurate measurement of extended protein degradation rates
Chan, C., Martin, P., Liptrott, N. J., Siccardi, M., Almond, L., & Owen, A. (2017). Incompatibility of chemical protein synthesis inhibitors with accurate measurement of extended protein degradation rates. PHARMACOLOGY RESEARCH & PERSPECTIVES, 5(5). doi:10.1002/prp2.359
In vitro characterisation of solid drug nanoparticle compositions of efavirenz in a brain endothelium cell line
Curley, P., Giardiello, M., Liptrott, N. J., Dickens, D., Moss, D. M., Hobson, J. J., . . . Owen, A. (2017). In vitro characterisation of solid drug nanoparticle compositions of efavirenz in a brain endothelium cell line. Journal of Interdisciplinary Nanomedicine, 2(3), 157-169. doi:10.1002/jin2.32
The Effect of Gene Variants on Levonorgestrel Pharmacokinetics When Combined With Antiretroviral Therapy Containing Efavirenz or Nevirapine
Neary, M., Lamorde, M., Olagunju, A., Darin, K. M., Merry, C., Byakika-Kibwika, P., . . . Scarsi, K. K. (2017). The Effect of Gene Variants on Levonorgestrel Pharmacokinetics When Combined With Antiretroviral Therapy Containing Efavirenz or Nevirapine. CLINICAL PHARMACOLOGY & THERAPEUTICS, 102(3), 529-536. doi:10.1002/cpt.667
Dual-stimuli responsive injectable nanogel/solid drug nanoparticle nanocomposites for release of poorly soluble drugs
Town, A., Gurjar, R., Giardiello, M., Briggs, M., Akhtar, R., Siccardi, M., & McDonald, T. (2017). Dual-stimuli responsive injectable nanogel/solid drug nanoparticle nanocomposites for release of poorly soluble drugs. In ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY Vol. 254. doi:10.1039/C6NR07858C
Transdermal delivery with microneedle patches using in silico modelling
Rajoli, R. K. R., Flexner, C., Owen, A., Donnelly, R., & Siccardi, M. (2017). Transdermal delivery with microneedle patches using in silico modelling. Belfast.
Simulating Intestinal Transporter and Enzyme Activity in a Physiologically Based Pharmacokinetic Model for Tenofovir Disoproxil Fumarate
Moss, D. M., Domanico, P., Watkins, M., Park, S., Randolph, R., Wring, S., . . . Owen, A. (2017). Simulating Intestinal Transporter and Enzyme Activity in a Physiologically Based Pharmacokinetic Model for Tenofovir Disoproxil Fumarate. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 61(7). doi:10.1128/AAC.00105-17
Dual-stimuli responsive injectable microgel/solid drug nanoparticle nanocomposites for release of poorly soluble drugs
Town, A. R., Giardiello, M., Gurjar, R., Siccardi, M., Briggs, M. E., Akhtar, R., & McDonald, T. O. (2017). Dual-stimuli responsive injectable microgel/solid drug nanoparticle nanocomposites for release of poorly soluble drugs. Nanoscale, 9(19), 6302-6314. doi:10.1039/c6nr07858c
Interaction of Rifampin and Darunavir-Ritonavir or Darunavir-Cobicistat <i>In Vitro</i>
Roberts, O., Khoo, S., Owen, A., & Siccardi, M. (2017). Interaction of Rifampin and Darunavir-Ritonavir or Darunavir-Cobicistat <i>In Vitro</i>. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 61(5). doi:10.1128/AAC.01776-16
Physiologically Based Pharmacokinetic Modeling to Predict Drug-Drug Interactions with Efavirenz Involving Simultaneous Inducing and Inhibitory Effects on Cytochromes
Marzolini, C., Rajoli, R., Battegay, M., Elzi, L., Back, D., & Siccardi, M. (2017). Physiologically Based Pharmacokinetic Modeling to Predict Drug-Drug Interactions with Efavirenz Involving Simultaneous Inducing and Inhibitory Effects on Cytochromes. CLINICAL PHARMACOKINETICS, 56(4), 409-420. doi:10.1007/s40262-016-0447-7
Use of a physiologically based pharmacokinetic model to simulate drug–drug interactions between antineoplastic and antiretroviral drugs
Molto, J., Rajoli, R., Back, D. J., Valle, M., Miranda, C., Owen, A., . . . Siccardi, M. (2017). Use of a physiologically based pharmacokinetic model to simulate drug–drug interactions between antineoplastic and antiretroviral drugs. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 72(3), 805-811. doi:10.1093/jac/dkw485
Computational Predictive Models for Nanomedicine
Computational Predictive Models for Nanomedicine (2017). In Unknown Book (pp. 379-402). Wiley. doi:10.1002/9783527800681.ch15
A physiologically based pharmacokinetic model to predict the superparamagnetic iron oxide nanoparticles (SPIONs) accumulation in vivo
Silva, A. H., Lima, E. J., Mansilla, M. V., Zysler, R. D., Mojica Pisciotti, M. L., Locatelli, C., . . . Siccardi, M. (2017). A physiologically based pharmacokinetic model to predict the superparamagnetic iron oxide nanoparticles (SPIONs) accumulation in vivo. EUROPEAN JOURNAL OF NANOMEDICINE, 9(2), 79-90. doi:10.1515/ejnm-2017-0001
Efavirenz Is Predicted To Accumulate in Brain Tissue: an In Silico, In Vitro, and In Vivo Investigation
Curley, P., Rajoli, R. K. R., Moss, D. M., Liptrott, N. J., Letendre, S., Owen, A., & Siccardi, M. (2017). Efavirenz Is Predicted To Accumulate in Brain Tissue: an <i>In Silico</i>, <i>In Vitro</i>, and <i>In Vivo</i> Investigation. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 61(1). doi:10.1128/AAC.01841-16
Integrated pharmacokinetic modelling for accelerated nanomedicine translation
Siccardi, M., Löffler, B., Balogh, L., & Owen, A. (2017). Integrated pharmacokinetic modelling for accelerated nanomedicine translation. European Journal of Nanomedicine, 9(1), 1-3. doi:10.1515/ejnm-2016-0041
Six year manufacturing to human clinical trial programme for the first oral dosed HIV nanomedicines
Giardiello, M., McDonald, T., Liptrott, N., Martin, P., Smith, D., Siccardi, M., . . . Rannard, S. (2017). Six year manufacturing to human clinical trial programme for the first oral dosed HIV nanomedicines. In ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY Vol. 254. Retrieved from https://www.webofscience.com/
USE OF MRNA SUPPRESSION TO ESTIMATE CYP3A4 PROTEIN DEGRADATION RATE CONSTANT IN PRIMARY HUMAN HEPATOCYTES
Chan, C. Y., Roberts, O., Hassan, N., Liptrott, N., Siccardi, M., Almond, L., & Owen, A. (2017). USE OF MRNA SUPPRESSION TO ESTIMATE CYP3A4 PROTEIN DEGRADATION RATE CONSTANT IN PRIMARY HUMAN HEPATOCYTES. In DRUG METABOLISM AND PHARMACOKINETICS Vol. 32 (pp. S109). doi:10.1016/j.dmpk.2016.10.099
2016
Simulation of long-acting administration of antituberculosis agents using pharmacokinetic modelling
Rajoli, R. K. R., Podany, A., Swindells, S., Flexner, C., Owen, A., & Siccardi, M. (2016). Simulation of long-acting administration of antituberculosis agents using pharmacokinetic modelling. Liverpool.
Accelerated oral nanomedicine discovery from miniaturized screening to clinical production exemplified by paediatric HIV nanotherapies
Giardiello, M., Liptrott, M. J., McDonald, T. O., Moss, D., Siccardi, M., Martin, P., . . . Owen, A. (2016). Accelerated oral nanomedicine discovery from miniaturized screening to clinical production exemplified by paediatric HIV nanotherapies. Nature Communications, 7. doi:10.1038/ncomms13184
Development and validation of an LC-MS/MS assay for the quantification of efavirenz in different biological matrices
Curley, P., Siccardi, M., Moss, D. M., & Owen, A. (2016). Development and validation of an LC-MS/MS assay for the quantification of efavirenz in different biological matrices. BIOANALYSIS, 8(20), 2125-2134. doi:10.4155/bio-2016-0021
Towards a rational design of solid drug nanoparticles with optimised pharmacological properties.
Siccardi, M., Martin, P., Smith, D., Curley, P., McDonald, T., Giardiello, M., . . . Owen, A. (2016). Towards a rational design of solid drug nanoparticles with optimised pharmacological properties.. Journal of interdisciplinary nanomedicine, 1(3), 110-123. doi:10.1002/jin2.21
Long-acting injectable formulations for children and adolescents using PBPK modelling
Rajoli, R. K. R., Back, D., Rannard, S., Flexner, C., Owen, A., & Siccardi, M. (2016). Long-acting injectable formulations for children and adolescents using PBPK modelling. Swansea.
Validation of computational approaches for antiretroviral dose optimization
Siccardi, M., Dickinson, L., & Owen, A. (n.d.). Validation of computational approaches for antiretroviral dose optimization. Antimicrobial Agents and Chemotherapy, 60, 3838-3839. doi:10.1128/AAC.00094-16
Validation of Computational Approaches for Antiretroviral Dose Optimization (vol 60, pg 3838, 2016)
Siccardi, M., Dickinson, L., & Owen, A. (2016). Validation of Computational Approaches for Antiretroviral Dose Optimization (vol 60, pg 3838, 2016). ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 61(1). Retrieved from http://gateway.webofknowledge.com/
Simulation of the impact of rifampicin on once-daily darunavir/ritonavir pharmacokinetics and dose adjustment strategies: a population pharmacokinetic approach
Dickinson, L., Winston, A., Boffito, M., Khoo, S., Back, D., & Siccardi, M. (2016). Simulation of the impact of rifampicin on once-daily darunavir/ritonavir pharmacokinetics and dose adjustment strategies: a population pharmacokinetic approach. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 71(4), 1041-1045. doi:10.1093/jac/dkv439
Predicting Utility of Long-Acting Injectables in Paediatric Patients With PBPK Models
Rajoli, R. K. R., Back, D., Rannard, S., Owen, A., & Siccardi, M. (2016). Predicting Utility of Long-Acting Injectables in Paediatric Patients With PBPK Models. Poster session presented at the meeting of Conference on Retroviral and Opportunistic Infections. Boston, MA, USA.
Effect of CYP2B6 variants on levonorgestrel pharmacokinetics when combined with efavirenz based antiretroviral therapy.
Neary, M. G., Lamorde, M., Olagunju, A., Darin, K., Merry, C., Byakika-Kibwika, P., . . . Scarsi, K. (n.d.). Effect of CYP2B6 variants on levonorgestrel pharmacokinetics when combined with efavirenz based antiretroviral therapy.. In CROI. Boston, MA, USA.
Interaction of Darunavir/Ritonavir and Darunavir/Cobicistat With Rifampicin In Vitro
Roberts, O., Back, D., Khoo, S., Owen, A., & Siccardi, M. (2016). Interaction of Darunavir/Ritonavir and Darunavir/Cobicistat With Rifampicin In Vitro. In CROI. Boston, USA.
Towards a computational prediction of nanoparticle pharmacokinetics and distribution
Siccardi, M., & Owen, A. (n.d.). Towards a computational prediction of nanoparticle pharmacokinetics and distribution. Journal of In Silico & In Vitro Pharmacology, 02(01). doi:10.21767/2469-6692.10008
2015
Physiologically Based Pharmacokinetic Modelling to Inform Development of Intramuscular Long-Acting Nanoformulations for HIV
Rajoli, R. K. R., Back, D. J., Rannard, S., Meyers, C. L. F., Flexner, C., Owen, A., & Siccardi, M. (2015). Physiologically Based Pharmacokinetic Modelling to Inform Development of Intramuscular Long-Acting Nanoformulations for HIV. CLINICAL PHARMACOKINETICS, 54(6), 639-650. doi:10.1007/s40262-014-0227-1
Prediction of Infant Exposure to Maternal Drugs From Breast Milk Using PBPK Modeling
Olagunju, A., Rajoli, R., Bolaji, O., Back, D., Khoo, S., Owen, A., & Siccardi, M. (2016, February 21). Prediction of Infant Exposure to Maternal Drugs From Breast Milk Using PBPK Modeling. In CROI.
Prevalence and type of drug-drug interactions involving ART in patients attending a specialist HIV outpatient clinic in Kampala, Uganda
Seden, K., Merry, C., Hewson, R., Siccardi, M., Lamorde, M., Byakika-Kibwika, P., . . . Khoo, S. H. (2015). Prevalence and type of drug-drug interactions involving ART in patients attending a specialist HIV outpatient clinic in Kampala, Uganda. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 70(12), 3317-3322. doi:10.1093/jac/dkv259
Predicting Utility of Long-Acting Injectables in Paediatric Patients With PBPK Models
Rajoli, R. K. R., Siccardi, M., Owen, A., Back, D., & Rannard, S. (2016, February 22). Predicting Utility of Long-Acting Injectables in Paediatric Patients With PBPK Models. In Conference on Retroviral and Opportunistic Infections. Boston, MA. Retrieved from http://www.croiconference.org/
Class-specific relative genetic contribution for key antiretroviral drugs
Siccardi, M., Olagunju, A., Simiele, M., D'Avolio, A., Calcagno, A., Di Perri, G., . . . Owen, A. (2015). Class-specific relative genetic contribution for key antiretroviral drugs. Journal of Antimicrobial Chemotherapy, 70(11), 3074-3079. doi:10.1093/jac/dkv207
Successful pharmacogenetics-based optimization of unboosted atazanavir plasma exposure in HIV-positive patients: a randomized, controlled, pilot study (the REYAGEN study)
Bonora, S., Rusconi, S., Calcagno, A., Bracchi, M., Vigano, O., Cusato, J., . . . Di Perri, G. (2015). Successful pharmacogenetics-based optimization of unboosted atazanavir plasma exposure in HIV-positive patients: a randomized, controlled, pilot study (the REYAGEN study). JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 70(11), 3096-3099. doi:10.1093/jac/dkv208
Augmented Inhibition of CYP3A4 in Human Primary Hepatocytes by Ritonavir Solid Drug Nanoparticles
Martin, P., Giardiello, M., McDonald, T. C., Smith, D., Siccardi, M., Rannard, S. P., & Owen, A. (2015). Augmented Inhibition of CYP3A4 in Human Primary Hepatocytes by Ritonavir Solid Drug Nanoparticles. MOLECULAR PHARMACEUTICS, 12(10), 3556-3568. doi:10.1021/acs.molpharmaceut.5b00204
Validation and clinical application of a method to quantify nevirapine in dried blood spots and dried breast-milk spots
Olagunju, A., Amara, A., Waitt, C., Else, L., Penchala, S. D., Bolaji, O., . . . Khoo, S. (2015). Validation and clinical application of a method to quantify nevirapine in dried blood spots and dried breast-milk spots. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 70(10), 2816-2822. doi:10.1093/jac/dkv174
Applications of physiologically based pharmacokinetic modeling for the optimization of anti-infective therapies
Moss, D. M., Marzolini, C., Rajoli, R. K. R., & Siccardit, M. (2015). Applications of physiologically based pharmacokinetic modeling for the optimization of anti-infective therapies. EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 11(8), 1203-1217. doi:10.1517/17425255.2015.1037278
Breast Milk Pharmacokinetics of Efavirenz and Breastfed Infants' Exposure in Genetically Defined Subgroups of Mother-Infant Pairs: An Observational Study
Olagunju, A., Bolaji, O., Amara, A., Waitt, C., Else, L., Adejuyigbe, E., . . . Owen, A. (2015). Breast Milk Pharmacokinetics of Efavirenz and Breastfed Infants' Exposure in Genetically Defined Subgroups of Mother-Infant Pairs: An Observational Study. Clin Infect Dis, 61(3), 453-463. doi:10.1093/cid/civ317
The Application of Nanotechnology to Drug Delivery in Medicine
McDonald, T. O., Siccardi, M., Moss, D., Liptrott, N., Giardiello, M., Rannard, S., & Owen, A. (2015). The Application of Nanotechnology to Drug Delivery in Medicine. In Nanoengineering (pp. 173-223). Elsevier. doi:10.1016/b978-0-444-62747-6.00007-5
Misoprostol-induced fever and genetic polymorphisms in drug transporters <i>SLCO1B1</i> and <i>ABCC4</i> in women of Latin American and European ancestry
Alfirevic, A., Durocher, J., Elati, A., Leon, W., Dickens, D., Raedisch, S., . . . Winikoff, B. (2015). Misoprostol-induced fever and genetic polymorphisms in drug transporters <i>SLCO1B1</i> and <i>ABCC4</i> in women of Latin American and European ancestry. PHARMACOGENOMICS, 16(9), 919-928. doi:10.2217/pgs.15.53
Flow cytometric analysis of the physical and protein-binding characteristics of solid drug nanoparticle suspensions
Liptrott, N. J., Giardiello, M., Hunter, J. W., Tatham, L., Tidbury, L. R., Siccardi, M., . . . Owen, A. (2015). Flow cytometric analysis of the physical and protein-binding characteristics of solid drug nanoparticle suspensions. NANOMEDICINE, 10(9), 1407-1421. doi:10.2217/NNM.14.77
Development, validation and clinical application of a novel method for the quantification of efavirenz in dried breast milk spots using LC-MS/MS
Olagunju, A., Bolaji, O. O., Amara, A., Waitt, C., Else, L., Soyinka, J., . . . Khoo, S. (2015). Development, validation and clinical application of a novel method for the quantification of efavirenz in dried breast milk spots using LC-MS/MS. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 70(2), 555-561. doi:10.1093/jac/dku420
Development, validation and clinical application of a novel method for the quantification of efavirenz in dried breast milk spots using LC-MS/MS.
Olagunju, A., Bolaji, O. O., Amara, A., Waitt, C., Else, L., Soyinka, J., . . . Khoo, S. (2015). Development, validation and clinical application of a novel method for the quantification of efavirenz in dried breast milk spots using LC-MS/MS.. The Journal of antimicrobial chemotherapy, 70(2), 555-561.
Impact of body weight on virological and immunological responses to efavirenz-containing regimens in HIV-infected, treatment-naive adults
Marzolini, C., Sabin, C., Raffi, F., Siccardi, M., Mussini, C., Launay, O., . . . Battegay, M. (2015). Impact of body weight on virological and immunological responses to efavirenz-containing regimens in HIV-infected, treatment-naive adults. AIDS, 29(2), 193-200. doi:10.1097/QAD.0000000000000530
Chapter 2.2 The Application of Nanotechnology to Drug Delivery in Medicine
McDonald, T. O., Siccardi, M., Moss, D., Liptrott, N., Giardiello, M., Rannard, S., & Owen, A. (2015). Chapter 2.2 The Application of Nanotechnology to Drug Delivery in Medicine. In Nanoengineering (pp. 173-223). Elsevier. doi:10.1016/b978-0-444-62747-6.00007-5
Interactions of antiretroviral drugs with the SLC22A1 (OCT1) drug transporter
Moss, D. M., Liptrott, N. J., Siccardi, M., & Owen, A. (2015). Interactions of antiretroviral drugs with the SLC22A1 (OCT1) drug transporter. FRONTIERS IN PHARMACOLOGY, 6. doi:10.3389/fphar.2015.00078
Use of In Vitro to In Vivo Extrapolation to Predict the Optimal Strategy for Patients Switching from Efavirenz to Maraviroc or Nevirapine
Schipani, A., Back, D., Owen, A., Davies, G., Khoo, S., & Siccardi, M. (2015). Use of In Vitro to In Vivo Extrapolation to Predict the Optimal Strategy for Patients Switching from Efavirenz to Maraviroc or Nevirapine. CLINICAL PHARMACOKINETICS, 54(1), 107-116. doi:10.1007/s40262-014-0184-8
2014
<i>CYP2B6</i> 516G>T (rs3745274) and Smoking Status Are Associated With Efavirenz Plasma Concentration in a Serbian Cohort of HIV Patients
Olagunju, A., Siccardi, M., Amara, A., Jevtovic, D., Kusic, J., Owen, A., & Dragovic, G. (2014). <i>CYP2B6</i> 516G>T (rs3745274) and Smoking Status Are Associated With Efavirenz Plasma Concentration in a Serbian Cohort of HIV Patients. THERAPEUTIC DRUG MONITORING, 36(6), 734-738. doi:10.1097/FTD.0000000000000098
A multisystem investigation of raltegravir association with intestinal tissue: implications for pre-exposure prophylaxis and eradication
Moss, D. M., Curley, P., Shone, A., Siccardi, M., & Owen, A. (2014). A multisystem investigation of raltegravir association with intestinal tissue: implications for pre-exposure prophylaxis and eradication. Journal of Antimicrobial Chemotherapy, 69(12), 3275-3281. doi:10.1093/jac/dku312
A multisystem investigation of raltegravir association with intestinal tissue: implications for pre-exposure prophylaxis and eradication
Moss, D. M., Curley, P., Shone, A., Siccardi, M., & Owen, A. (2014). A multisystem investigation of raltegravir association with intestinal tissue: implications for pre-exposure prophylaxis and eradication. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 69(12), 3275-3281. doi:10.1093/jac/dku312
Simulation of the impact of rifampicin on darunavir/ritonavir PK and dose adjustment strategies in HIV‐infected patients: a population PK approach
Dickinson, L., Winston, A., Boffito, M., Khoo, S., Back, D., & Siccardi, M. (2014). Simulation of the impact of rifampicin on darunavir/ritonavir PK and dose adjustment strategies in HIV‐infected patients: a population PK approach. Journal of the International AIDS Society, 17(4S3). doi:10.7448/ias.17.4.19586
Optimisation of Intramuscular Sustained Release-Nano-Formulations Using In Silico Modelling
Rajoli, R. K. R., Back, D., Rannard, S., Owen, A., & Siccardi, M. (2014). Optimisation of Intramuscular Sustained Release-Nano-Formulations Using In Silico Modelling. Poster session presented at the meeting of Conference On Retroviruses And Opportunistic Infections. Boston, MA, USA.
Antiretroviral Solid Drug Nanoparticles with Enhanced Oral Bioavailability: Production, Characterization, and In Vitro–In Vivo Correlation
McDonald, T. O., Giardiello, M., Martin, P., Siccardi, M., Liptrott, N. J., Roberts, P., . . . Owen, A. (2014). Antiretroviral Solid Drug Nanoparticles with Enhanced Oral Bioavailability: Production, Characterization, and In Vitro–In Vivo Correlation. Advanced Healthcare Materials, 3(3), 400-411. doi:10.1002/adhm.201300280
<i>CYP3A4</i>*22 (c.522-191 C>T; rs35599367) is associated with lopinavir pharmacokinetics in HIV-positive adults
Olagunju, A., Schipani, A., Siccardi, M., Egan, D., Khoo, S., Back, D., & Owen, A. (2014). <i>CYP3A4</i>*22 (c.522-191 C>T; rs35599367) is associated with lopinavir pharmacokinetics in HIV-positive adults. PHARMACOGENETICS AND GENOMICS, 24(9), 459-463. doi:10.1097/FPC.0000000000000073
Flow cytometric analysis of the physical and protein-binding characteristics of solid drug nanoparticle suspensions
Liptrott, N., Giardiello, M., Hunter, J. W., Tatham, L., Tidbury, L. R., Siccardi, M., . . . Owen, A. (2014). Flow cytometric analysis of the physical and protein-binding characteristics of solid drug nanoparticle suspensions. Nanomedicine (London).
Highlights of research at the University of Liverpool and activity of the British Society for Nanomedicine
Curley, P., Liptrott, N., Tatham, L., Siccardi, M., & Owen, A. (2014). Highlights of research at the University of Liverpool and activity of the British Society for Nanomedicine. Poster session presented at the meeting of 7th CLINAM Conference and Exhibition. Basel, Switzerland.
Multi-system investigation of the mechanisms for raltegravir association with intestinal tissue after oral administration
Moss, D., Curley, P., Shone, A., Siccardi, M., & Owen, A. (2014). Multi-system investigation of the mechanisms for raltegravir association with intestinal tissue after oral administration. Poster session presented at the meeting of 21st Conference on Retroviruses and Opportunistic Infections. Boston, USA.
Optimizing nanomedicine pharmacokinetics using physiologically based pharmacokinetics modelling
Moss, D. M., & Siccardi, M. (2014). Optimizing nanomedicine pharmacokinetics using physiologically based pharmacokinetics modelling. BRITISH JOURNAL OF PHARMACOLOGY, 171(17), 3963-3979. doi:10.1111/bph.12604
Polymorphisms in <i>SLC34A1</i> and <i>ABCC2</i> genes are related with altered renal tubular function in HIV-positive patients receiving tenofovir
Alvarez, E., Owen, A., Martin Carbonero, L., Siccardi, M., Valencia, E., Moreno, V., . . . Rodriguez-Novoa, S. (2014). Polymorphisms in <i>SLC34A1</i> and <i>ABCC2</i> genes are related with altered renal tubular function in HIV-positive patients receiving tenofovir. In ANTIVIRAL THERAPY Vol. 19 (pp. A11). Retrieved from https://www.webofscience.com/
Simulation of the impact of rifampicin on darunavir/ritonavir PK and dose adjustment strategies in HIV-infected patients: a population PK approach
Dickinson, L., Winston, A., Boffito, M., Khoo, S., Back, D., & Siccardi, M. (2014). Simulation of the impact of rifampicin on darunavir/ritonavir PK and dose adjustment strategies in HIV-infected patients: a population PK approach. J Int AIDS Soc, 17(4 Supp), 19586.
Simulation of the impact of rifampicin on darunavir/ritonavir PK and dose adjustment strategies in HIV-infected patients: a population PK approach.
Dickinson, L., Winston, A., Boffito, M., Khoo, S., Back, D., & Siccardi, M. (2014). Simulation of the impact of rifampicin on darunavir/ritonavir PK and dose adjustment strategies in HIV-infected patients: a population PK approach.. Journal of the International AIDS Society, 17(4 Suppl 3), 19586. doi:10.7448/ias.17.4.19586
The in vivo effects of solid drug nanoparticle and conventional efavirenz on anxiogenesis in rodents
Curley, P., Giardiello, M., Liptrott, N., Martin, P., McDonald, T., Siccardi, M., . . . Owen, A. (2014). The in vivo effects of solid drug nanoparticle and conventional efavirenz on anxiogenesis in rodents. Poster session presented at the meeting of 21st Conference on Retroviruses and Opportunistic Infections. Boston, USA.
2013
Rilpivirine Inhibits Drug Transporters ABCB1, SLC22A1, and SLC22A2 <i>In Vitro</i>
Moss, D. M., Liptrott, N. J., Curley, P., Siccardi, M., Back, D. J., & Owen, A. (2013). Rilpivirine Inhibits Drug Transporters ABCB1, SLC22A1, and SLC22A2 <i>In Vitro</i>. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 57(11), 5612-5618. doi:10.1128/AAC.01421-13
Physiologically based pharmacokinetic models for the optimization of antiretroviral therapy: recent progress and future perspective
Siccardi, M., Rajoli, R. K. R., Curley, P., Olagunju, A., Moss, D., & Owen, A. (2013). Physiologically based pharmacokinetic models for the optimization of antiretroviral therapy: recent progress and future perspective. FUTURE VIROLOGY, 8(9), 871-890. doi:10.2217/fvl.13.67
Erratum to: Prediction of Drug–Drug Interactions Between Various Antidepressants and Efavirenz or Boosted Protease Inhibitors Using a Physiologically Based Pharmacokinetic Modelling Approach
Siccardi, M., Marzolini, C., Seden, K., Almond, L., Kirov, A., Khoo, S., . . . Back, D. (2013). Erratum to: Prediction of Drug–Drug Interactions Between Various Antidepressants and Efavirenz or Boosted Protease Inhibitors Using a Physiologically Based Pharmacokinetic Modelling Approach. Clinical Pharmacokinetics, 52(7), 613-614. doi:10.1007/s40262-013-0066-5
Predicting intestinal absorption of raltegravir using a population-based ADME simulation
Moss, D. M., Siccardi, M., Back, D. J., & Owen, A. (2013). Predicting intestinal absorption of raltegravir using a population-based ADME simulation. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 68(7), 1627-1634. doi:10.1093/jac/dkt084
Prediction of drug-drug Interactions Between Various Antidepressants and Efavirenz or Boosted Protease Inhibitors Using a Physiologically Based Pharmacokinetic Modelling Approach
Siccardi, M., Marzolini, C., Seden, K., Almond, L., Kirov, A., Khoo, S., . . . Back, D. (2013). Prediction of drug-drug Interactions Between Various Antidepressants and Efavirenz or Boosted Protease Inhibitors Using a Physiologically Based Pharmacokinetic Modelling Approach. CLINICAL PHARMACOKINETICS, 52(7), 583-592. doi:10.1007/s40262-013-0056-7
Intracellular accumulation of ritonavir combined with different protease inhibitors and correlations between concentrations in plasma and peripheral blood mononuclear cells
D'Avolio, A., Simiele, M., Calcagno, A., Siccardi, M., Larovere, G., Agati, S., . . . Bonora, S. (2013). Intracellular accumulation of ritonavir combined with different protease inhibitors and correlations between concentrations in plasma and peripheral blood mononuclear cells. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 68(4), 907-910. doi:10.1093/jac/dks484
Correlates of Efavirenz Exposure in Chilean Patients Affected With Human Immunodeficiency Virus Reveals a Novel Association With a Polymorphism in the Constitutive Androstane Receptor
Cortes, C. P., Siccardi, M., Chaikan, A., Owen, A., Zhang, G., & la Porte, C. J. L. (2013). Correlates of Efavirenz Exposure in Chilean Patients Affected With Human Immunodeficiency Virus Reveals a Novel Association With a Polymorphism in the Constitutive Androstane Receptor. THERAPEUTIC DRUG MONITORING, 35(1), 78-83. doi:10.1097/FTD.0b013e318274197e
Enhanced Pharmacological Properties of Efavirenz Formulated as Solid Drug Nanoparticles
Martin, P., Liptrott, N., McDonald, T., Giardiello, M., Roberts, P., Curley, P., . . . Owen, A. (2013). Enhanced Pharmacological Properties of Efavirenz Formulated as Solid Drug Nanoparticles. In 20th Conference on Retroviruses and Opportunistic Infections. Atlanta, USA.
Investigation of the potential interactions of efavirenz and the GABAa receptor utilising an in silico approach
Curley, P., Schipani, A., Siccardi, M., & Owen, A. (2013). Investigation of the potential interactions of efavirenz and the GABAa receptor utilising an in silico approach. Poster session presented at the meeting of Manchester Life Sciences PhD Conference. Manchester, UK.
Nanomedicines for HIV therapy.
Siccardi, M., Martin, P., McDonald, T. O., Liptrott, N. J., Giardiello, M., Rannard, S., & Owen, A. (2013). Nanomedicines for HIV therapy.. Therapeutic delivery, 4(2), 153-156. doi:10.4155/tde.12.156
Physiologically based pharmacokinetic models for the optimization of antiretroviral therapy: recent progress and future perspective
Siccardi, M., Rajoli, R. K. R., Curley, P., Olagunju, A., Moss, D., & Owen, A. (2013). Physiologically based pharmacokinetic models for the optimization of antiretroviral therapy: recent progress and future perspective. Future Virology,, 8(9), 871-890.
Prediction of Etravirine Pharmacogenetics using a Physiologically Based Pharmacokinetic approach
Siccardi, M., Olagunju, A., Curley, P., Hobson, J., Khoo, S., Back, D., & Owen, A. (2013). Prediction of Etravirine Pharmacogenetics using a Physiologically Based Pharmacokinetic approach. In 20th Conference on Retroviruses and Opportunistic Infections. Atlanta, USA.
Use of a physiologically-based pharmacokinetic model to simulate artemether dose adjustment for overcoming the drug-drug interaction with efavirenz
Siccardi, M., Olagunju, A., Seden, K., Ebrahimjee, F., Rannard, S., Back, D., & Owen, A. (2013). Use of a physiologically-based pharmacokinetic model to simulate artemether dose adjustment for overcoming the drug-drug interaction with efavirenz. In Silico Pharmacology, 1(4).
Use of a physiologically-based pharmacokinetic model to simulate artemether dose adjustment for overcoming the drug-drug interaction with efavirenz.
Siccardi, M., Olagunju, A., Seden, K., Ebrahimjee, F., Rannard, S., Back, D., & Owen, A. (2013). Use of a physiologically-based pharmacokinetic model to simulate artemether dose adjustment for overcoming the drug-drug interaction with efavirenz.. In silico pharmacology, 1, 4. doi:10.1186/2193-9616-1-4
Utilising In Vitro-In Vivo extrapolation to investigate efavirenz penetration into the central nervous system
Curley, P., Martin, P., Liptrott, N., Back, D., Owen, A., & Siccardi, M. (2013). Utilising In Vitro-In Vivo extrapolation to investigate efavirenz penetration into the central nervous system. Poster session presented at the meeting of 14th International Workshop on Clinical Pharmacology of HIV Therapy. Netherlands.
2012
Efavirenz in an obese HIV-infected patient - a report and an <i>in vitro</i>-<i>in vivo</i> extrapolation model indicate risk of underdosing
de Roche, M., Siccardi, M., Stoeckle, M., Livio, F., Back, D., Battegay, M., & Marzolini, C. (2012). Efavirenz in an obese HIV-infected patient - a report and an <i>in vitro</i>-<i>in vivo</i> extrapolation model indicate risk of underdosing. ANTIVIRAL THERAPY, 17(7), 1381-1384. doi:10.3851/IMP2107
Negative Predictive Value of <i>IL28B</i>, <i>SLC28A2</i>, and <i>CYP27B1</i> SNPs and Low RBV Plasma Exposure for Therapeutic Response to PEG/IFN-RBV Treatment
D'Avolio, A., Ciancio, A., Siccardi, M., Smedile, A., Simiele, M., Cusato, J., . . . Di Perri, G. (2012). Negative Predictive Value of <i>IL28B</i>, <i>SLC28A2</i>, and <i>CYP27B1</i> SNPs and Low RBV Plasma Exposure for Therapeutic Response to PEG/IFN-RBV Treatment. THERAPEUTIC DRUG MONITORING, 34(6), 722-728. doi:10.1097/FTD.0b013e318272e55a
Prediction of drug-drug interactions between various antidepressants and ritonavir using a physiologically based pharmacokinetic model
Siccardi, M., Marzolini, C., Seden, K., Almond, L., Kirov, A., Khoo, S., . . . Back, D. (2012). Prediction of drug-drug interactions between various antidepressants and ritonavir using a physiologically based pharmacokinetic model. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 15, 60. doi:10.7448/IAS.15.6.18339
Pharmacokinetic and Pharmacodynamic Analysis of Efavirenz Dose Reduction Using an <i>In Vitro</i>-<i>In Vivo</i> Extrapolation Model
Siccardi, M., Almond, L., Schipani, A., Csajka, C., Marzolini, C., Wyen, C., . . . Back, D. (2012). Pharmacokinetic and Pharmacodynamic Analysis of Efavirenz Dose Reduction Using an <i>In Vitro</i>-<i>In Vivo</i> Extrapolation Model. CLINICAL PHARMACOLOGY & THERAPEUTICS, 92(4), 494-502. doi:10.1038/clpt.2012.61
Prophylactic Drug Monitoring of Itraconazole in an Oncohematological Pediatric Patient Population
Baietto, L., De Rosa, F. G., D'Avolio, A., Marra, C., Pace, S., Biasin, E., . . . Di Perri, G. (2012). Prophylactic Drug Monitoring of Itraconazole in an Oncohematological Pediatric Patient Population. THERAPEUTIC DRUG MONITORING, 34(5), 604-606. doi:10.1097/FTD.0b013e31826a701e
Determinants of darunavir cerebrospinal fluid concentrations: impact of once-daily dosing and pharmacogenetics
Calcagno, A., Yilmaz, A., Cusato, J., Simiele, M., Bertucci, R., Siccardi, M., . . . Bonora, S. (2012). Determinants of darunavir cerebrospinal fluid concentrations: impact of once-daily dosing and pharmacogenetics. AIDS, 26(12), 1529-1533. doi:10.1097/QAD.0b013e3283553619
Influence of CYP2B6 and ABCB1 SNPs on nevirapine plasma concentrations in Burundese HIV-positive patients using dried sample spot devices
Calcagno, A., D'Avolio, A., Simiele, M., Cusato, J., Rostagno, R., Libanore, V., . . . Di Perri, G. (2012). Influence of CYP2B6 and ABCB1 SNPs on nevirapine plasma concentrations in Burundese HIV-positive patients using dried sample spot devices. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 74(1), 134-140. doi:10.1111/j.1365-2125.2012.04163.x
Divalent Metals and pH Alter Raltegravir Disposition <i>In Vitro</i>
Moss, D. M., Siccardi, M., Murphy, M., Piperakis, M. M., Khoo, S. H., Back, D. J., & Owen, A. (2012). Divalent Metals and pH Alter Raltegravir Disposition <i>In Vitro</i>. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 56(6), 3020-3026. doi:10.1128/AAC.06407-11
Inosine Triphosphatase Polymorphisms and Ribavirin Pharmacokinetics as Determinants of Ribavirin-Associate Anemia in Patients Receiving Standard Anti-HCV Treatment
D'Avolio, A., Ciancio, A., Siccardi, M., Smedile, A., Baietto, L., Simiele, M., . . . Di Perri, G. (2012). Inosine Triphosphatase Polymorphisms and Ribavirin Pharmacokinetics as Determinants of Ribavirin-Associate Anemia in Patients Receiving Standard Anti-HCV Treatment. THERAPEUTIC DRUG MONITORING, 34(2), 165-170. doi:10.1097/FTD.0b013e31824bf778
Intrapatient and Interpatient Pharmacokinetic Variability of Raltegravir in the Clinical Setting
Siccardi, M., D'Avolio, A., Rodriguez-Novoa, S., Cuenca, L., Simiele, M., Baietto, L., . . . Di Perri, G. (2012). Intrapatient and Interpatient Pharmacokinetic Variability of Raltegravir in the Clinical Setting. THERAPEUTIC DRUG MONITORING, 34(2), 232-235. doi:10.1097/FTD.0b013e31824aa50a
Once daily maraviroc 300 mg or 150 mg in combination with ritonavir-boosted darunavir 800/100 mg
Okoli, C., Siccardi, M., Thomas-William, S., Dufty, N., Khonyongwa, K., Ainsworth, J., . . . Taylor, S. (2012). Once daily maraviroc 300 mg or 150 mg in combination with ritonavir-boosted darunavir 800/100 mg. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 67(3), 671-674. doi:10.1093/jac/dkr493
Pharmacokinetics of Lamivudine and Lamivudine-Triphosphate after Administration of 300 Milligrams and 150 Milligrams Once Daily to Healthy Volunteers: Results of the ENCORE 2 Study
Else, L. J., Jackson, A., Puls, R., Hill, A., Fahey, P., Lin, E., . . . Boffito, M. (2012). Pharmacokinetics of Lamivudine and Lamivudine-Triphosphate after Administration of 300 Milligrams and 150 Milligrams Once Daily to Healthy Volunteers: Results of the ENCORE 2 Study. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 56(3), 1427-1433. doi:10.1128/AAC.05599-11
Association of <i>ABCC10</i> polymorphisms with nevirapine plasma concentrations in the German Competence Network for HIV/AIDS
Liptrott, N. J., Pushpakom, S., Wyen, C., Faetkenheuer, G., Hoffmann, C., Mauss, S., . . . Owen, A. (2012). Association of <i>ABCC10</i> polymorphisms with nevirapine plasma concentrations in the German Competence Network for HIV/AIDS. PHARMACOGENETICS AND GENOMICS, 22(1), 10-19. doi:10.1097/FPC.0b013e32834dd82e
Association of ABCC10 polymorphisms with nevirapine plasma concentrations in the German Competence Network for HIV/AIDS
Liptrott, N. J., Pushpakom, S., Wyen, C., Fätkenheuer, G., Hoffmann, C., Mauss, S., . . . Owen, A. (2012). Association of ABCC10 polymorphisms with nevirapine plasma concentrations in the German Competence Network for HIV/AIDS. Pharmacogenetics and Genomics, 22(1), 10-19. doi:10.1097/fpc.0b013e32834dd82e
Investigation of the potential interactions of efavirenz with the GABAa receptor
Curley, P., Schipani, A., Egan, D., Siccardi, M., Wyen, C., Fätkenheuer, G., & Owen, A. (2012). Investigation of the potential interactions of efavirenz with the GABAa receptor. Poster session presented at the meeting of British Pharmacology Society Winter Meeting. London, UK.
Once daily maraviroc 300mg or 150mg OD in combination with ritonavir -boosted darunavir 800/100mg.
Okoli, C., Siccardi, M., Thomas-William, S., Dufty, N., Khonyongwa, K., Ainsworth, J., . . . Taylor, S. (2012). Once daily maraviroc 300mg or 150mg OD in combination with ritonavir -boosted darunavir 800/100mg.. Journal of Antimicrobial Chemotherapy, 67, 671-674.
PHARMACOKINETIC AND PHARMACODYNAMIC ANALYSIS OF EFAVIRENZ DOSE REDUCTION USING A PHYSIOLOGICALLY-BASED DYNAMIC MODEL
Siccardi, M., Almond, L., Schipani, A., Csajka, C., Marzolini, C., Edwards, D., . . . Back, D. (2012). PHARMACOKINETIC AND PHARMACODYNAMIC ANALYSIS OF EFAVIRENZ DOSE REDUCTION USING A PHYSIOLOGICALLY-BASED DYNAMIC MODEL. CLINICAL PHARMACOLOGY & THERAPEUTICS, 91, S104. Retrieved from https://www.webofscience.com/
Pharmacokinetics of lamivudine and lamivudine-triphosphate after administration of 300 milligrams and 150 milligrams once daily to healthy volunteers: results of the ENCORE 2 study
Else, L., Jackson, A., Puls, R., Hill, A., Fahey, P., Lin, E., . . . Boffito, M. (2012). Pharmacokinetics of lamivudine and lamivudine-triphosphate after administration of 300 milligrams and 150 milligrams once daily to healthy volunteers: results of the ENCORE 2 study. Antimicrob Agents Chemother, 56(3), 1427-1433.
Prophylactic drug monitoring of itraconazole in an oncohematological pediatric patient population
Baietto, L., De Rosa, F. G., D'Avolio, A., Marra, C., Pace, S., Biasin, E., . . . Di Perri, G. (2012). Prophylactic drug monitoring of itraconazole in an oncohematological pediatric patient population. Ther Drug Monit, 34(5), 604-606. doi:10.1097/FTD.0b013e31826a701e00007691-201210000-00020
2011
Influence of CYP2B6 and ABCB1 SNPs on Nevirapine Plasma Concentrations in Burundese HIV-positive Patients Using Dried Sample Spot Devices
Calcagno, A., D'Avolio, A., Simiele, M., Cusato, J., Rostagno, R., Libanore, V., . . . Di Perri, G. (2011). Influence of CYP2B6 and ABCB1 SNPs on Nevirapine Plasma Concentrations in Burundese HIV-positive Patients Using Dried Sample Spot Devices. British Journal of Clinical Pharmacology, no. doi:10.1111/j.1365-2125.2011.04163.x
Ribavirin Pharmacokinetics and Interleukin 28B Plus Cytochrome P450 27B1 Single-Nucleotide Polymorphisms as Predictors of Response to Pegylated Interferon/Ribavirin Treatment in Patients Infected with Hepatitis C Virus Genotype 1/4
D'Avolio, A., Ciancio, A., Siccardi, M., Baietto, L., Simiele, M., Cariti, G., . . . Di Perri, G. (2011). Ribavirin Pharmacokinetics and Interleukin 28B Plus Cytochrome P450 27B1 Single-Nucleotide Polymorphisms as Predictors of Response to Pegylated Interferon/Ribavirin Treatment in Patients Infected with Hepatitis C Virus Genotype 1/4. HEPATOLOGY, 54(6), 2278-2279. doi:10.1002/hep.24636
Cytochrome P450 2B6 (<i>CYP2B6</i>) and constitutive androstane receptor (<i>CAR</i>) polymorphisms are associated with early discontinuation of efavirenz-containing regimens
Wyen, C., Hendra, H., Siccardi, M., Platten, M., Jaeger, H., Harrer, T., . . . Owen, A. (2011). Cytochrome P450 2B6 (<i>CYP2B6</i>) and constitutive androstane receptor (<i>CAR</i>) polymorphisms are associated with early discontinuation of efavirenz-containing regimens. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 66(9), 2092-2098. doi:10.1093/jac/dkr272
Pharmacokinetics of switching unboosted atazanavir coadministered with tenofovir disoproxil fumarate from 400 mg once daily to 200 mg twice daily in HIV-positive patients
Bonora, S., de Requena, D. G., D'Avolio, A., Calcagno, A., Tettoni, M., Siccardi, M., . . . Di Perri, G. (2011). Pharmacokinetics of switching unboosted atazanavir coadministered with tenofovir disoproxil fumarate from 400 mg once daily to 200 mg twice daily in HIV-positive patients. ANTIVIRAL THERAPY, 16(4), 499-504. doi:10.3851/IMP1802
Ceftriaxone bone penetration in patients with septic non-union of the tibia
Garazzino, S., Aprato, A., Baietto, L., D'Avolio, A., Maiello, A., De Rosa, F. G., . . . Di Perri, G. (2011). Ceftriaxone bone penetration in patients with septic non-union of the tibia. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 15(6), E415-E421. doi:10.1016/j.ijid.2011.03.003
Evaluation of the Mean Corpuscular Volume of Peripheral Blood Mononuclear Cells of HIV Patients by a Coulter Counter To Determine Intracellular Drug Concentrations
Simiele, M., D'Avolio, A., Baietto, L., Siccardi, M., Sciandra, M., Agati, S., . . . Di Perri, G. (2011). Evaluation of the Mean Corpuscular Volume of Peripheral Blood Mononuclear Cells of HIV Patients by a Coulter Counter To Determine Intracellular Drug Concentrations. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 55(6), 2976-2978. doi:10.1128/AAC.01236-10
Integration of population pharmacokinetics and pharmacogenetics: an aid to optimal nevirapine dose selection in HIV-infected individuals
Schipani, A., Wyen, C., Mahungu, T., Hendra, H., Egan, D., Siccardi, M., . . . Back, D. J. (2011). Integration of population pharmacokinetics and pharmacogenetics: an aid to optimal nevirapine dose selection in HIV-infected individuals. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 66(6), 1332-1339. doi:10.1093/jac/dkr087
A HPLC-MS method for the simultaneous quantification of fourteen antiretroviral agents in peripheral blood mononuclear cell of HIV infected patients optimized using medium corpuscular volume evaluation
D'Avolio, A., Simiele, M., Siccardi, M., Baietto, L., Sciandra, M., Oddone, V., . . . Di Perri, G. (2011). A HPLC-MS method for the simultaneous quantification of fourteen antiretroviral agents in peripheral blood mononuclear cell of HIV infected patients optimized using medium corpuscular volume evaluation. JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 54(4), 779-788. doi:10.1016/j.jpba.2010.10.011
Raltegravir Is a Substrate for SLC22A6: a Putative Mechanism for the Interaction between Raltegravir and Tenofovir
Moss, D. M., Kwan, W. S., Liptrott, N. J., Smith, D. L., Siccardi, M., Khoo, S. H., . . . Owen, A. (2011). Raltegravir Is a Substrate for SLC22A6: a Putative Mechanism for the Interaction between Raltegravir and Tenofovir. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 55(2), 879-887. doi:10.1128/AAC.00623-10
INTRACELLULAR ACCUMULATION OF RITONAVIR ASSOCIATED WITH DIFFERENT BOOSTED PIS
D'Avolio, A., Simiele, M., Siccardi, M., Baietto, L., Agati, S., Cusato, J., . . . Di Perri, G. (2011). INTRACELLULAR ACCUMULATION OF RITONAVIR ASSOCIATED WITH DIFFERENT BOOSTED PIS. In INFECTION Vol. 39 (pp. S24). Retrieved from https://www.webofscience.com/
TENOFOVIR AND EMTRICITABINE CSF-TO-PLASMA RATIOS CORRELATE TO THE EXTENT OF BLOOD BRAIN-BARRIER DAMAGE
Calcagno, A., Bonora, S., Simiele, M., Audagnotto, S., Siccardi, M., de Requena, D. G., . . . Di Perri, G. (2011). TENOFOVIR AND EMTRICITABINE CSF-TO-PLASMA RATIOS CORRELATE TO THE EXTENT OF BLOOD BRAIN-BARRIER DAMAGE. In INFECTION Vol. 39 (pp. S19-S20). Retrieved from https://www.webofscience.com/
2010
Maraviroc is a substrate for OATP1B1 <i>in vitro</i> and maraviroc plasma concentrations are influenced by SLCO1B1 521 T>C polymorphism
Siccardi, M., D'Avolio, A., Nozza, S., Simiele, M., Baietto, L., Stefani, F. R., . . . Owen, A. (2010). Maraviroc is a substrate for OATP1B1 <i>in vitro</i> and maraviroc plasma concentrations are influenced by SLCO1B1 521 T>C polymorphism. PHARMACOGENETICS AND GENOMICS, 20(12), 759-765. doi:10.1097/FPC.0b013e3283402efb
Population Pharmacokinetic Modeling of the Association between 63396C→T Pregnane X Receptor Polymorphism and Unboosted Atazanavir Clearance
Schipani, A., Siccardi, M., D'Avolio, A., Baietto, L., Simiele, M., Bonora, S., . . . Owen, A. (2010). Population Pharmacokinetic Modeling of the Association between 63396C→T Pregnane X Receptor Polymorphism and Unboosted Atazanavir Clearance. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 54(12), 5242-5250. doi:10.1128/AAC.00781-10
Population Pharmacokinetic Modeling of the Association between 63396C→T Pregnane X Receptor Polymorphism and Unboosted Atazanavir Clearance
Schipani, A., Siccardi, M., D'Avolio, A., Baietto, L., Simiele, M., Bonora, S., . . . Owen, A. (2010). Population Pharmacokinetic Modeling of the Association between 63396C→T Pregnane X Receptor Polymorphism and Unboosted Atazanavir Clearance. Antimicrobial Agents and Chemotherapy, 54(12), 5242-5250. doi:10.1128/aac.00781-10
HPLC-MS method for the quantification of nine anti-HIV drugs from dry plasma spot on glass filter and their long term stability in different conditions
D'Avolio, A., Simiele, M., Siccardi, M., Baietto, L., Sciandra, M., Bonora, S., & Di Perri, G. (2010). HPLC-MS method for the quantification of nine anti-HIV drugs from dry plasma spot on glass filter and their long term stability in different conditions. JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 52(5), 774-780. doi:10.1016/j.jpba.2010.02.026
Development, Validation, and Routine Application of a High-Performance Liquid Chromatography Method Coupled with a Single Mass Detector for Quantification of Itraconazole, Voriconazole, and Posaconazole in Human Plasma
Baietto, L., D'Avolio, A., Ventimiglia, G., De Rosa, F. G., Siccardi, M., Simiele, M., . . . Di Perri, G. (2010). Development, Validation, and Routine Application of a High-Performance Liquid Chromatography Method Coupled with a Single Mass Detector for Quantification of Itraconazole, Voriconazole, and Posaconazole in Human Plasma. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 54(8), 3408-3413. doi:10.1128/AAC.01807-09
Raltegravir Penetration in Seminal Plasma of Healthy Volunteers
Calcagno, A., Bonora, S., D'Avolio, A., Siccardi, M., Simiele, M., Chiesa, M., . . . Di Perri, G. (2010). Raltegravir Penetration in Seminal Plasma of Healthy Volunteers. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 54(6), 2744-2745. doi:10.1128/AAC.00241-10
Validation of a rapid and sensitive high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) assay for the simultaneous determination of existing and new antiretroviral compounds
Else, L., Watson, V., Tjia, J., Hughes, A., Siccardi, M., Khoo, S., & Back, D. (2010). Validation of a rapid and sensitive high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) assay for the simultaneous determination of existing and new antiretroviral compounds. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 878(19), 1455-1465. doi:10.1016/j.jchromb.2010.03.036
Impairment in kidney tubular function in patients receiving tenofovir is associated with higher tenofovir plasma concentrations
Rodriguez-Novoa, S., Labarga, P., D'Avolio, A., Barreiro, P., Albalate, M., Vispo, E., . . . Soriano, V. (2010). Impairment in kidney tubular function in patients receiving tenofovir is associated with higher tenofovir plasma concentrations. AIDS, 24(7), 1064-1066. doi:10.1097/QAD.0b013e32833202e2
2002 SLC28A2 65C>T PREDICT SUSTAINED VIROLOGICAL RESPONSE IN PATIENTS WITH HEPATITIS C TREATED WITH INTERFERON AND RIBAVIRIN, CONSIDERING ALL HCV GENOTYPE AND GENOTYPE 1/4
D'Avolio, A., Ciancio, A., Siccardi, M., Baietto, L., Simiele, M., Patanella, S., . . . Di Perri, G. (2010). 2002 SLC28A2 65C>T PREDICT SUSTAINED VIROLOGICAL RESPONSE IN PATIENTS WITH HEPATITIS C TREATED WITH INTERFERON AND RIBAVIRIN, CONSIDERING ALL HCV GENOTYPE AND GENOTYPE 1/4. Journal of Hepatology, 52, S463. doi:10.1016/s0168-8278(10)61193-2
A Validated High-Performance Liquid Chromatography-Ultraviolet Method for Quantification of the CCR5 Inhibitor Maraviroc in Plasma of HIV-Infected Patients
D'Avolio, A., Simiele, M., Baietto, L., Siccardi, M., Sciandra, M., Patanella, S., . . . Di Perri, G. (2010). A Validated High-Performance Liquid Chromatography-Ultraviolet Method for Quantification of the CCR5 Inhibitor Maraviroc in Plasma of HIV-Infected Patients. THERAPEUTIC DRUG MONITORING, 32(1), 86-92. doi:10.1097/FTD.0b013e3181cacbd0
A filter-based cross-sectional analysis of an HIV-positive, HAART-treated cohort in rural Burundi: pharmacokinetics, pharmacogenetics and viral load
Calcagno, A., Milia, M. G., D'Avolio, A., Ndayishimiyae, P., Dusabimana, P., Bonora, S., . . . Di Perri, G. (2010). A filter-based cross-sectional analysis of an HIV-positive, HAART-treated cohort in rural Burundi: pharmacokinetics, pharmacogenetics and viral load. Journal of the International AIDS Society, 13(Suppl 4), P179. doi:10.1186/1758-2652-13-s4-p179
Altered plasma levels of nevirapine after commencing rifampicin-containing TB regimens in Malawi
Chaponda, M., Nyirenda, W., Watson, V., White, S., Van Oosterhout, J., Lalloo, D., . . . Khoo, S. (2010). Altered plasma levels of nevirapine after commencing rifampicin-containing TB regimens in Malawi. In HIV MEDICINE Vol. 11 (pp. 6). Retrieved from https://www.webofscience.com/
Analysis of determinants of long-term efficacy of unboosted atazanavir-based regimens in the clinical setting
Bonora, S., Calcagno, A., Viganò, O., Bigliano, P., Rusconi, S., Trentini, L., . . . Di Perri, G. (2010). Analysis of determinants of long-term efficacy of unboosted atazanavir-based regimens in the clinical setting. Journal of the International AIDS Society, 13(Suppl 4), P48. doi:10.1186/1758-2652-13-s4-p48
Development and validation of a simultaneous extraction procedure for HPLC-MS quantification of daptomycin, amikacin, gentamicin, and rifampicin in human plasma
Baietto, L., D'Avolio, A., De Rosa, F. G., Garazzino, S., Michelazzo, M., Ventimiglia, G., . . . Di Perri, G. (2010). Development and validation of a simultaneous extraction procedure for HPLC-MS quantification of daptomycin, amikacin, gentamicin, and rifampicin in human plasma. ANALYTICAL AND BIOANALYTICAL CHEMISTRY, 396(2), 791-798. doi:10.1007/s00216-009-3263-1
Maraviroc is a substrate for OATP1B1 in vitro and maraviroc plasma concentrations are influenced by SLCO1B1 521 T>C polymorphism
Siccardi, M., D'Avolio, A., Nozza, S., Simiele, M., Baietto, L., Stefani, F. R., . . . Owen, A. (2010). Maraviroc is a substrate for OATP1B1 in vitro and maraviroc plasma concentrations are influenced by SLCO1B1 521 T>C polymorphism. Pharmacogenet Genomics, 20(12), 759-765. doi:10.1097/FPC.0b013e3283402efb01213011-201012000-00004
Population pharmacokinetics of unboosted atazanavir and influence of the pregnane -x- receptor PXR 63396C>T
Schipani, A., Siccardi, M., D'Avolio, A., Baietto, L., Bonora, S., Davies, G., . . . Owen, A. (2010). Population pharmacokinetics of unboosted atazanavir and influence of the pregnane -x- receptor PXR 63396C>T. In HIV MEDICINE Vol. 11 (pp. 24). Retrieved from https://www.webofscience.com/
SLCO3A1 expression is a major determinant of atazanavir PBMC penetration in HIV-infected patients
Siccardi, M., D'Avolio, A., Baietto, L., Simiele, M., Bonora, S., Back, D. J., . . . Owen, A. (2010). SLCO3A1 expression is a major determinant of atazanavir PBMC penetration in HIV-infected patients. Journal of the International AIDS Society, 13(Suppl 4), P178.
2009
Lack of interaction between raltegravir and cyclosporin in an HIV-infected liver transplant recipient
Di Biagio, A., Rosso, R., Siccardi, M., D'Avolio, A., Bonora, S., & Viscoli, C. (2009). Lack of interaction between raltegravir and cyclosporin in an HIV-infected liver transplant recipient. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 64(4), 874-875. doi:10.1093/jac/dkp269
New HPLC-MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib, and nilotinib in human plasma
De Francia, S., D'Avolio, A., De Martino, F., Pirro, E., Baietto, L., Siccardi, M., . . . Di Perri, G. (2009). New HPLC-MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib, and nilotinib in human plasma. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 877(18-19), 1721-1726. doi:10.1016/j.jchromb.2009.04.028
Simultaneous Quantification of Linezolid, Rifampicin, Levofloxacin, and Moxifloxacin in Human Plasma Using High-Performance Liquid Chromatography With UV
Baietto, L., D'Avolio, A., De Rosa, F. G., Garazzino, S., Patanella, S., Siccardi, M., . . . Di Perri, G. (2009). Simultaneous Quantification of Linezolid, Rifampicin, Levofloxacin, and Moxifloxacin in Human Plasma Using High-Performance Liquid Chromatography With UV. THERAPEUTIC DRUG MONITORING, 31(1), 104-109. doi:10.1097/FTD.0b013e31819476fa
PHARMACOKINETICS AND PHARMACOGENETICS OF MARAVIROC IN THE CLINICAL SETTING
Siccardi, M., Bonora, S., Nozza, S., Castagna, A., D'Avolio, A., Michelazzo, M., . . . Di Perri, G. (2009). PHARMACOKINETICS AND PHARMACOGENETICS OF MARAVIROC IN THE CLINICAL SETTING. In INFECTION Vol. 37 (pp. 21). Retrieved from https://www.webofscience.com/
PHARMACOKINETICS OF RALTEGRAVIR IN THE CLINICAL SETTING
Calcagno, A., Bonora, S., Nozza, S., Castagna, A., Ripamonti, D., D'Avolio, A., . . . Di Perri, G. (2009). PHARMACOKINETICS OF RALTEGRAVIR IN THE CLINICAL SETTING. In INFECTION Vol. 37 (pp. 69). Retrieved from https://www.webofscience.com/
Validation of an ultra-sensitive high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) assay for simultaneous determination of 11 anti-retroviral compounds
Else, L., Watson, V., Tjia, J., Siccardi, M., Khoo, S., & Back, D. (2009). Validation of an ultra-sensitive high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) assay for simultaneous determination of 11 anti-retroviral compounds. In BRITISH JOURNAL OF CLINICAL PHARMACOLOGY Vol. 68 (pp. 276). Retrieved from https://www.webofscience.com/
2008
An HPLC-PDA Method for the Simultaneous Quantification of the HIV Integrase Inhibitor Raltegravir, the New Nonnucleoside Reverse Transcriptase Inhibitor Etravirine, and 11 Other Antiretroviral Agents in the Plasma of HIV-Infected Patients
D'Avolio, A., Baietto, L., Siccardi, M., Sciandra, M., Simiele, M., Oddone, V., . . . Di Perri, G. (2008). An HPLC-PDA Method for the Simultaneous Quantification of the HIV Integrase Inhibitor Raltegravir, the New Nonnucleoside Reverse Transcriptase Inhibitor Etravirine, and 11 Other Antiretroviral Agents in the Plasma of HIV-Infected Patients. THERAPEUTIC DRUG MONITORING, 30(6), 662-669. doi:10.1097/FTD.0b013e318189596d
Glycopeptide Bone Penetration in Patients with Septic Pseudoarthrosis of the Tibia
Garazzino, S., Aprato, A., Baietto, L., D'Avolio, A., Maiello, A., De Rosa, F. G., . . . Di Perri, G. (2008). Glycopeptide Bone Penetration in Patients with Septic Pseudoarthrosis of the Tibia. CLINICAL PHARMACOKINETICS, 47(12), 793-805. doi:10.2165/0003088-200847120-00004
Association of a single-nucleotide polymorphism in the pregnane X receptor (<i>PXR</i> 63396C→T) with reduced concentrations of unboosted atazanavir
Siccardi, M., D'Avolio, A., Baietto, L., Gibbons, S., Sciandra, M., Colucci, D., . . . Owen, A. (2008). Association of a single-nucleotide polymorphism in the pregnane X receptor (<i>PXR</i> 63396C→T) with reduced concentrations of unboosted atazanavir. CLINICAL INFECTIOUS DISEASES, 47(9), 1222-1225. doi:10.1086/592304
A new assay based on solid-phase extraction procedure with LC-MS to measure plasmatic concentrations of tenofovir and emtricitabine in HIV infected patients
D'Avolio, A., Sciandra, M., Siccardi, M., Baietto, L., de Requena, D. G., Bonora, S., & Di Perri, G. (2008). A new assay based on solid-phase extraction procedure with LC-MS to measure plasmatic concentrations of tenofovir and emtricitabine in HIV infected patients. JOURNAL OF CHROMATOGRAPHIC SCIENCE, 46(6), 524-528. doi:10.1093/chromsci/46.6.524
The use of trough ribavirin concentration to predict sustained virological response and haematological toxicity in HIV/HCV-co-infected patients treated with ribavirin and pegylated interferon
Marucco, D. A., de Requena, D. G., Bonora, S., Tettoni, C., Bonasso, M., De Blasi, T., . . . Di Perri, G. (2008). The use of trough ribavirin concentration to predict sustained virological response and haematological toxicity in HIV/HCV-co-infected patients treated with ribavirin and pegylated interferon. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 61(4), 919-924. doi:10.1093/jac/dkn013
Tipranavir (TPV) genotypic inhibitory quotient predicts virological response at 48 weeks to TPV-based salvage regimens
de Requena, D. G., Bonora, S., Calcagno, A., D'Avolio, A., Siccardi, M., Fontana, S., . . . Di Perri, G. (2008). Tipranavir (TPV) genotypic inhibitory quotient predicts virological response at 48 weeks to TPV-based salvage regimens. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 52(3), 1066-1071. doi:10.1128/AAC.01063-07
A simple and fast method for quantification of ertapenem using meropenem as internal standard in human plasma in a clinical setting
D'Avolio, A., Baietto, L., De Rosa, F. G., Garazzino, S., Sciandra, M., Siccardi, M., . . . Di Perri, G. (2008). A simple and fast method for quantification of ertapenem using meropenem as internal standard in human plasma in a clinical setting. THERAPEUTIC DRUG MONITORING, 30(1), 90-94. doi:10.1097/FTD.0b013e31815f4f7e
HPLC-MS method for the simultaneous quantification of the new HIV protease inhibitor darunavir, and 11 other antiretroviral agents in plasma of HIV-infected patients (vol 859, pg 234, 2007)
D'Avolio, A., Siccardi, M., Sciandra, M., Baietto, L., Bonora, S., Trentind, L., & Di Perri, G. (2008). HPLC-MS method for the simultaneous quantification of the new HIV protease inhibitor darunavir, and 11 other antiretroviral agents in plasma of HIV-infected patients (vol 859, pg 234, 2007). JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 862(1-2), 265. doi:10.1016/j.jchromb.2007.11.015
A simple and fast method for quantification of ertapenem using meropenem as internal standard in human plasma in a clinical setting
D'Avolio, A., Baietto, L., DeRosa, F. G., Garazzino, S., Sciandra, M., Siccardi, M., . . . Di Perri, G. (2008). A simple and fast method for quantification of ertapenem using meropenem as internal standard in human plasma in a clinical setting. Ther Drug Monit, 30(1), 90-94. doi:10.1097/FTD.0b013e31815f4f7e00007691-200802000-00014
Glycopeptide bone penetration in patients with septic pseudoarthrosis of the tibia
Garazzino, S., Aprato, A., Baietto, L., D'Avolio, A., Maiello, A., De Rosa, F. G., . . . Di Perri, G. (2008). Glycopeptide bone penetration in patients with septic pseudoarthrosis of the tibia. Clin Pharmacokinet, 47(12), 793-805. doi:10.2165/0003088-200847120-0000447124
Plasma concentrations of boosted and unboosted atazanavir are predicted by 63396C>T SNP in the PXR gene
Siccardi, M., D'Avolio, A., Baietto, L., Calcagno, A., Gibbons, S. E., Sciandra, M., . . . Owen, A. (2008). Plasma concentrations of boosted and unboosted atazanavir are predicted by 63396C>T SNP in the PXR gene. Journal of the International AIDS Society, 11(Suppl 1), P233. doi:10.1186/1758-2652-11-s1-p233
2007
Clinically significant drug interaction between tipranavir-ritonavir and phenobarbital in an HIV-infected subject
Bonora, S., Calcagno, A., Fontana, S., D'Avolio, A., Siccardi, M., Gobbi, F., & Di Perri, G. (2007). Clinically significant drug interaction between tipranavir-ritonavir and phenobarbital in an HIV-infected subject. CLINICAL INFECTIOUS DISEASES, 45(12), 1654-1655. doi:10.1086/523722
HPLC-MS method for the simultaneous quantification of the new HIV protease inhibitor darunavir, and 11 other antiretroviral agents in plasma of HIV-infected patients
D'Avolio, A., Siccardi, M., Sciandra, M., Lorena, B., Bonora, S., Trentini, L., & Di Perri, G. (2007). HPLC-MS method for the simultaneous quantification of the new HIV protease inhibitor darunavir, and 11 other antiretroviral agents in plasma of HIV-infected patients. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 859(2), 234-240. doi:10.1016/j.jchromb.2007.10.003
A simple and sensitive assay for determining plasma tipranavir concentration in the clinical setting by new HPLC method
D'Avolio, A., Sciandra, M., Siccardi, M., Baietto, L., de Requena, D. G., Bonora, S., & Di Perri, G. (2007). A simple and sensitive assay for determining plasma tipranavir concentration in the clinical setting by new HPLC method. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 848(2), 374-378. doi:10.1016/j.jchromb.2006.10.030
2006
Unexpected drug-drug interaction between tipranavir/ritonavir and enfuvirtide
de Requena, D. G., Calcagno, A., Bonora, S., Ladetto, L., D'Avolio, A., Sciandra, M., . . . Di Perri, G. (2006). Unexpected drug-drug interaction between tipranavir/ritonavir and enfuvirtide. AIDS, 20(15), 1977-1979. doi:10.1097/01.aids.0000247121.19951.fa
Validation of liquid/liquid extraction method coupled with HPLC-UV for measurement of ribavirin plasma levels in HCV-positive patients
D'Avolio, A., Ibañez, A., Sciandra, M., Siccardi, M., de Requena, D. G., Bonora, S., & Di Perri, G. (2006). Validation of liquid/liquid extraction method coupled with HPLC-UV for measurement of ribavirin plasma levels in HCV-positive patients. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 835(1-2), 127-130. doi:10.1016/j.jchromb.2006.03.019
Unexpected drug-drug interaction between tipranavir/ritonavir and enfuvirtide
Gonzalez de Requena, D., Calcagno, A., Bonora, S., Ladetto, L., D'Avolio, A., Sciandra, M., . . . Di Perri, G. (2006). Unexpected drug-drug interaction between tipranavir/ritonavir and enfuvirtide. AIDS, 20(15), 1977-1979. doi:10.1097/01.aids.0000247121.19951.fa00002030-200610030-00012